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Unintended pregnancy among young women continues to be an issue in the United States 
(Finer & Zolna, 2011).  Although several safe and highly effective contraceptives are available, 
nearly half of all pregnancies in the United States are unintended, with the majority occurring 
among women between the ages of 18-24,  who are frequently college students, unmarried, low 
income, or not planning to conceive (Finer & Henshaw, 2006; CDC, 2013).  Unintended 
pregnancies often result from inappropriate or inconsistent contraceptive use (Secura, Allsworth, 
Madden, Mullersman, & Peiper, 2010), and one in five unintended pregnancies ends in abortion 
(Pazol, Creanga, Burley, Hayes, & Jamieson, 2013).  Long-acting reversible contraceptive 
methods (LARCs) are safe and highly effective contraceptive methods that can be used to 
prevent unintended pregnancy, but are currently only being utilized by a small portion of women 
- 5% of contraceptive users - in the United States (Secura et al.; Mosher & Jones, 2010).   
Based on the 2011 enrollment report, the patient population of Student Health and 
Counseling Services (SHCS) of California State University, East Bay (CSUEB) consists of 
approximately 13,160 enrolled students, of which 60% (7,959) are female and 40% (5,201) are 
male, with an average age of 26 (Baker, Malhotra, & Weitzman, 2013; Office of Planning & 
Institutional Research, CSUEB, 2012).  An American College Health Association (ACHA) 
survey conducted in spring 2010 found that the unintended pregnancy rate was reported as 4.9% 
among CSUEB respondents compared to national rates of 5%.   Among all 23 CSU campuses, 
currently enrolled students are able to go to any nearby CSU, Student Health Services (SHS) for 
care if needed, but none of the CSU SHS listed the provision of LARCs service on the SHS 
home page by online search. 




Assisting students in maintaining their optimal health to allow them to pursue academic 
and career goals is the main mission of Student Health and Counseling Services (SHCS, 2014).  
According to the 2012 ACHA, approximately 65% of college students reported having sexual 
partners within the last 12 months, and 49% of them reported not using any contraceptive 
method (ACHA-NHCA II, 2012).  Furthermore, in 2013, the American College Health 
Association surveyed college students nationwide about contraceptive use, with a 34% response 
rate that consisted of 96,611 respondents (ACHA-NCHA II, 2013).  Of the respondents, 46.5% 
reported not using any contraceptive methods during their last sexual intercourse within the past 
30 days.  The usage rate for intrauterine contraception (IUC) was reported at 5.5%, implant 
contraception was reported at 2.4%, and birth control shot was reported at 4.3%.  Therefore, 
helping students prevent unintended pregnancy, especially freshmen and newly transferred 
students, is one of the measures to help maintain their optimum health.   
Previous studies have shown that misperceptions about LARCs, lack of access, lack of 
education, and lack of training on IUC use among health professionals are common issues, and 
may be the major reason for their underuse (Secura et al., 2010; Khan & Shaikh, 2013; 
Kavanaugh, Jerman, Ether, & Moskosy, 2012).  Family nurse practitioners can help these young 
women make an informed choice about contraception by providing evidence-based information 
and dispelling the misconceptions regarding LARCs.  The purpose of this project is to provide 
evidence-based information regarding LARCs use and discuss the integration of LARCs services 
into a primary care-focused student health clinic. 
Long-Acting Reversible Contraceptives (LARC) 




Long-acting reversible contraceptives (LARCs) include three types of intrauterine 
devices and one type of implant that provide highly effective contraception, rapid fertility 
reversal after removal, and are non-user dependent after placement.  
Intrauterine contraceptives 
The World Health Organization (WHO) supports intrauterine contraceptive (IUC) use in 
adolescents starting from menarche with a level 2 recommendation, “benefits outweigh the risks” 
(WHO, 2004).  Additionally, IUC is considered to be a first-line choice contraceptive method for 
both nulliparous and parous adolescents as recommended by the American College of 
Obstetricians and Gynecologists (ACOG) Committee Opinion in 2007 (Deans & Grimes, 2009; 
ACOG, 2007).  IUC is one of the most effective contraceptive methods for unintended 
pregnancies because it is long-acting, reversible, safe, and requires low user maintenance.  After 
adequate counseling, an IUC may be placed by a trained health care provider in an outpatient 
clinic.  Currently, the three IUC devices available in U.S. include the Copper T 380A (ParaGard) 
and two levonorgestrel intrauterine systems (LNG-IUS), Mirena and Skyla (Deans & Grimes, 
2009; Hatcher et al., 2011).   
The Copper T 380A IUD was introduced in the United States in 1988.  It is a non-
hormonal, polyethylene T-shaped copper containing device with barium sulfate for x-ray 
visibility, placed inside the uterus for contraceptive use for up to 10 years.  The device is 36 mm 
tall and 32 mm wide, and the total copper surface area is 380 ± 23 mm
²
.  The copper ions in the 
device prevent fertilization and implantation (Hatcher et al., 2011).  The Copper T can be used as 
emergency contraception within five days of unprotected sexual intercourse (Hatcher et al., 2011) 
and has greater than 99% efficacy at pregnancy prevention.  High efficacy and long duration of 




use have made copper IUDs the most common contraceptive method in developing countries, 
especially in China (Arrowsmith, Aicken, Saxena, & Majeed, 2012).   
There are currently two levonorgestrel intrauterine system (LNG-IUS) options available 
in the United States: Mirena and Skyla (Hatcher et al., 2011; Phelps, Murphy, & Godfrey, 2011; 
Medscape Reference, 2014).  The first LNG-IUS, Mirena, was approved for use in the United 
States in 2000 and is a small T-shaped IUC device that contains 52 mg levonorgestrel, and 
initially releases about 20 mcg daily into the uterine cavity, with the amount gradually 
decreasing to 10 mcg daily by the fifth year (Hatcher et al., 2011; Phelps et al., 2011; Medscape 
Reference, 2014).  The device is made of a Nova-T polyethylene frame with barium sulfate for 
x-ray visibility and a cylinder of a polydimethylsiloxane-levonorgestrel mixture molded around 
the vertical arm.  The device is 32 mm tall & 32 mm wide (Hatcher et al., 2011; Medscape 
Reference, 2014).  It is one of the most effective contraceptive methods and also has a number of 
non-contraceptive health benefits which include: decreasing menstrual blood loss, alleviating 
painful menstrual cycles, and protecting the endometrial layer during estrogen replacement 
therapy (Medscape Reference, 2014; Mansour, 2012).  The efficacy of the LNG-IUS in 
preventing pregnancy is greater than 99%, and it is approved for contraceptive use for up to 5 
years.   
The second LNG-IUS, Skyla, contains 13.5 mg levonorgestrel and is the newest IUC, 
added to the US market in 2013.  The device is 30 mm tall and 28 mm wide and releases about 
14 mcg per day of levonorgestrel into the uterine cavity initially (Medscape reference, 2014).  
The amount of levonorgestrel gradually decreases to 5 mcg daily after three years of use 
(Medscape Reference, 2014).  Levonorgestrel acts by thickening the cervical mucus to prevent 
sperm from entering into the uterus and changing the endometrium structure to prevent 




implantation.  This IUS prevents pregnancy for up to 3 years at greater than 99% efficacy.  It 
also can provide non-contraceptive benefits to some female users with a history of painful or 
heavy menstrual cycles by decreasing the lining of the endometrial layer, decreasing menstrual 
blood loss, and preventing painful menstrual cycles (Hatcher et al., 2011; Medscape Reference, 
2014; Mansour, 2012).    
Etonogestrel contraceptive implant 
The ENG-Implant is a single thin implant rod 4 cm long and 2 mm in diameter that is 
made of ethylene vinyl acetate and contains 68 mg of etonogestrel (3-keto-desogestrel), which is 
placed under the skin in the medial upper arm.  The ENG-Implant provides unsurpassed 
contraceptive efficacy by inhibiting ovulation and thickening cervical mucus.  It also provides 
effective contraception with a very low level of progestin and follicular phase estrogen that has 
been well tolerated, reportedly has decreased weight changes among users, and rare medical 
contraindications.  It also decreases menstrual blood loss and painful menstrual cycles for at least 
3 years.  The effectiveness of the ENG implant to prevent pregnancy is greater than 99% (6 
pregnancies in 20,648 cycles).  Return of fertility is rapid among users with etonogestrel levels 
undetectable within 1 week (Davies, Feng, Newton, Van Beek, & Coelingh-Bennink, 1993);  44 
of 47 women who were studied with ultrasound and serum progesterone levels ovulated within 1 
month post removal (Croxatto & Makarainen, 1998). 
Besides preventing unintended pregnancies, non-contraceptive benefits of LARCs can be 
used to help individuals with chronic medical conditions, such as anemia, heavy menstrual 
bleeding, and painful menstrual periods (Hatcher et al., 2011).   LARCs will be suitable for 
patients with chronic conditions who take medications which can cause adverse effects.  LARCs 




are especially appropriate for patients who are treating their medical conditions with teratogenic 
medications (US MEC, 2012).    
Local problem 
The Need for LARC services 
There are a few triggers leading this project’s initiation.  First, highly effective long-
acting reversible contraceptive methods are not available at SHCS, even though most other 
contraceptive methods are provided.  Second, students who are interested in LARC methods are 
referred to off-campus Planned Parenthood (PP) clinics or nearby community health centers for 
LARC placement services, but the nearby PP clinics have been closed due to financial 
difficulties (Mieszkowski, 2010).  Also, according to an on-line search, none of the 23 California 
State Universities (CSU), student health clinics currently lists the service of LARCs on their 
student health clinic’s home pages.   
Unintended pregnancy is a substantial social and economic problem in the United States.  
Even though there are many contraceptive choices available, 49% of the 6.4 million pregnancies 
every year in the United States are unintended (Trussell, 2007).  Among women 15-44, the rate 
of unintended pregnancies was 51 per 1,000 women, with the majority occurring among women 
aged 18-24, who are often unmarried, low-income, low-education level, and minority ethnicity 
(Finer, 2006).  In the U.S., unintended teenage pregnancy has a significant fiscal impact, costing 
taxpayers at least $10,900,000,000 annually (H.R.2678, 2011).  In 2009, there were nearly 
750,000 teenage pregnancies, and a total of 409,840 infants were born to 15-19 year-olds with a 
live birth rate of 39.1 per 1,000 women (CDC, 2011).  Women with an unintended pregnancy 
will usually delay prenatal care, which can affect the health of both the fetus and the woman.  




Pregnant teenagers also face more medical and socioeconomic concerns such as increased risk of 
pre-term delivery, low birth weight, neonatal mortality, delays to antenatal care, lower 
educational levels, higher rates of poverty, and other poorer “life outcomes” compared with 
women in their twenties and thirties (CDC, 2011; Chen et al., 2007).   
According to the 2013 American College Health Association survey of contraception use 
among U.S. college students (ACHA-NCHA II with n=96,611), the IUC usage rate was 5.5%.  
Of the respondents, 46.5% reported not using any contraceptive methods during sexual 
intercourse within the past 30 days.  About 18.8% of the female respondents reported using 
emergency contraceptive pills (“the morning after pill”) in the last 12 months and 1.9% of the 
respondents reported experiencing an unintended pregnancy in the past 12 months.   
Inappropriate or inconsistent contraceptive use is the most common cause of unintended 
pregnancy, (Secura et al., 2010) and approximately one in five unintended pregnancies ends in 
abortion (Pazol et al., 2013).  Due to the misuse or infrequent use of contraceptives, unintended 
teen pregnancy in the Unites States continues to be a persistent problem (Martinez, Copen, & 
Abma, 2011).  Prevention of unintended teen pregnancy is of particular importance to the health 
and quality of life for young people throughout the United States.   Additionally, improving 
maternal health is one of the United Nations Millennium Development Goals for 2015 (UNDP, 
2012).  Recommended strategies will effectively improve maternal health, such as increased 
contraceptive use and improved health care access.    
Student Health Services are outpatient clinics on college campuses that offer primary 
medical care and women’s health care to students. Generally, they are staffed by physicians, 
nurse practitioners, registered nurses, medical assistants, and counselors.  The mission of the 




Student Health Services is to assist students in achieving their academic and career goals by 
providing resources to help them maintain optimal health and to provide high quality, low cost 
health care to all enrolled students.  Highly effective long-acting reversible contraceptive 
methods, such as the implant contraceptive and IUC, are not listed as available services at the 
majority of on-campus Student Health Services (SHS) in California.   
Healthy Campus 2020, initiated by American College Health Association’s (ACHA) 
Healthy Campus Coalition and derived from Healthy People 2020, targets reducing unintended 
pregnancy, increasing contraception use, and facilitating emergency contraception access at SHS 
to meet the student family planning objectives by 2020.  Long-acting reversible contraception 
(LARC) methods are very safe and effective contraceptive methods that can be used to prevent 
unintended pregnancy, but are currently only being utilized by a small portion of women in the 
United States (Secura et al., 2010; Mosher & Jones, 2010).   Increased highly effective 
contraceptive method use and increased access to such health care options are recommended as 
strategies to improve family planning and maternal health by United Nations (UNDP, 2012).  
Integrating LARC services into College Student Health Services is needed to help the healthcare 
system effectively meet these goals.     
Intended Improvement  
The goal to add the highly effective, non-user dependent LARC methods to the services 
of SHCS for students will enhance SHCS’s mission to provide the best quality, low-cost health 
care to help students maintain their optimal health in order to pursue their academic and career 
goals.   




The first objective of this project is to study the clinical contraceptives services currently 
provided and continuing usage by individual students.  The second objective is to promote 
contraceptive use and add the service of highly effective LARC methods for sexually active 
students to lower students’ stress by reducing the number of off-campus referrals, to prevent 
unintended pregnancy, and to help students maintain optimal health conditions to pursue their 
university degrees and careers.  The third objective is to collaborate with the health promotion 
department to educate students and to promote the use of highly effective contraceptives.    
The purpose of this proposal is to add highly effective long-acting reversible 
contraceptives (LARCs) service at SHCS for university students to help maintain their optimal 
health, to treat medical conditions, and to prevent unintended pregnancies.    
Review of the Evidence 
Also, many misperceptions regarding the use of IUC among patients and health providers 
need to be addressed (Khan & Shaikh, 2013; Mansour, 2012) prior to integration of IUC services 
into a primary care focused student health clinic.  Providing the most up-to-date and accurate 
information about LARC methods will assist in dispelling rumors and myths.  Myths can be 
defined as a belief, often false or unproven, that have accrued around a person, phenomenon, or 
institution.  Rumors can be defined as unverified information of uncertain origin received from 
another (American Heritage Dictionary, 2000).  Misconceptions and rumors have negatively 
impacted the uptake of LARC methods.  The facts presented below will help address common 
misconceptions about the LARC methods.   
IUC & the Facts 




Although IUCs are safe, highly effective, and economical contraceptive methods, they 
are currently underutilized, especially among adolescents.  Clinical providers are still reluctant to 
provide the service due to misperceptions stemming from the 1970s.  Memories remain of the 
Dalkon Shield product, an IUC released in 1971 and withdrawn from the market in 1974, whose 
unique shape and its multifilament string tail caused removal difficulties, pelvic infections, septic 
abortions, and other infections (Cheng, 2000).  Approximately 200,000 claimants worldwide 
filed lawsuits against the manufacturer even after the product was withdrawn from the market in 
1974.   
Myths about IUC use and function abound, nevertheless the U.S. Medical Eligibility 
Criteria for Contraceptive Use, 2010 (U.S. MEC), and the U.S. Selected Practice 
Recommendations for Contraceptive Use, 2013 (U.S. SPR) for health care providers are 
excellent resources for education, implementation, continuing care, and management of IUC.   
A common misperception is the mechanism of action of an IUC.  An IUC is not an 
abortifacient (Phelps et al., 2011).  IUC alters the uterine environment by promoting a foreign-
body reaction inside the uterine cavity that prevents fertilization and/or implantation (Hatcher et 
al., 2011; Mansour, 2012).  With the copper IUD, copper repels sperm and generates an 
inflammatory foreign body reaction to prevent fertilization (Hatcher et al., 2011; Phelps et al., 
2011).  The LNG-IUS works by releasing high concentrations of LNG within the uterine cavity, 
which results in endometrial atrophy and  thickens the cervical mucus to create a barrier to sperm 
penetration, thereby preventing sperm-egg binding (Hatcher et al., 2011; Phelps et al., 2011).   
Historical problems with the Dalkon Shield have falsely created the belief that the IUC is 
not appropriate for nulliparous women.  The WHO and the ACOG, support the use of IUC in 




both nulliparous and parous adolescents (WHO SPR, 2004; ACOG, 2007; Mestad et al., 2011; 
Godfrey et al., 2010).  IUC for nulliparous use is a level 2 recommendation from the U.S. 
Medical Eligibility Criteria; the benefits of IUC generally outweigh the risks for women who 
have not had children (US MEC, 2010) (see appendix L).   
Similarly, misperceptions about infertility persist.  An IUD does not cause infertility and 
does not limit one’s chances of getting pregnant in the future.  Most cycles in women using 
LNG-IUS are ovulatory because there is no reduction in estradiol levels (Mansour, 2012).  For 
women wanting to conceive, the 12-month pregnancy rate (92%) following removal of LNG-
IUS is similar to women using natural family planning (Mansour, 2012).  Historically, there was 
concern that IUC increased the spread of sexually transmitted infections (STIs).  If STIs are not 
treated, they can scar the fallopian tubes and prevent women from getting pregnant.  Research 
shows that today’s IUC does not increase the risk of STIs and does not lead to infertility.  For 
women who are at a low risk of sexually transmitted infections, such as those who are in 
monogamous relationships, the risk of developing pelvic inflammatory disease (PID) with IUC 
use is less than 1 in 100 and is even less in women who use LNG-IUS (Mansour, 2012).  Women 
who use IUC and develop an STI or PID rarely need to have the device removed.  Mansour 
(2012) found that discontinuation rates due to PID were 0.5 and 2.0 per 100 women at 3 years 
(p=.013) for the LNG-IUS and copper IUD, respectively, and 0.8 and 2.2 per 100 women (p<.05), 
respectively, at 5 years.  When a woman develops an STI or PID, she should be treated with 
antibiotics right away.  The IUC can remain in place if symptoms improve within 72 hours.  If 
symptoms persist, the IUC should be removed (Hatcher et al., 2011).   
IUC does not increase the risk of ectopic pregnancy, regardless of whether a woman has 
had a prior ectopic pregnancy.  Ectopic pregnancy occurs 10 times more frequently in women 




who do not use contraceptives than in IUC users.  Mansour (2012) found that ectopic pregnancy 
rates were 0.045 and 0.22 per 100 LNG-IUS users at 1 and 5 years, respectively.  For women 
who did not use any contraception, an estimated rate was 1.4 per 100 pregnancies.  The U.S. 
MEC found no restriction to use for patients with history of ectopic pregnancy (US MEC, 2010).    
Mansour (2012) also found no significant abnormal cytopathological effects on the LNG-
IUS users in a 7-year long-term study of cervical smear samples.  Progestin-releasing intrauterine 
contraception has been shown to reduce the incidence of endometrial cancer because it is more 
effective in reducing endometrial hyperplasia than oral progestin, and the LNG-IUS also 
prevents endometrial polyps in women taking tamoxifen for up to 4.5 years (Hatcher et al., 2011; 
Mansour, 2012).  The copper IUC’s mechanism of action is unclear, but the endometrium 
alterations may be related to the presence of copper; (Hatcher et al., 2011) therefore, both types 
of IUCs may reduce the risk of endometrial cancer (Hatcher et al., 2011; Mansour, 2012).   
Literature Review 
The currently used intrauterine devices are very safe and more effective than other types 
of contraceptives (Secura et al., 2010). IUC efficacy is similar to sterilization at 99%, but fertility 
can be reversed rapidly after the device’s removal.  An IUC can be used by both parous or 
nulliparous adolescent women (ACOG, 2007).  However, it is currently underused among 
adolescents who are in the high risk group for unintended pregnancies, and this is largely due to 
a lack of knowledge regarding IUC.  Furthermore, clinical providers are often reluctant to 
provide IUC services due to historical problems with outmoded devices, ongoing misconceptions, 
and lack of training.   




A literature review was conducted to evaluate the effectiveness, acceptability, and 
continued use of these highly effective contraceptive methods by the young female population.  
Due to scarce data on long-acting reversible contraceptive (LARC) use among the adolescent 
group, it is important to determine whether LARCs are acceptable among this age group.  
Mestad et al. (2011) conducted a longitudinal, observational study in St. Louis, MO -- the 
Contraceptive CHOICE Project -- to promote LARC with no financial barriers and to evaluate 
use, satisfaction and comparison of continuation between LARC and non-LARC methods.  The 
LNG-IUS, Copper IUD, and subdermal implant are included among LARC methods.  Combined 
and progestin-only oral contraceptives, depot medroxyprogesterone acetate, the vaginal 
contraceptive ring, the transdermal contraceptive patch, and barrier methods are included in the 
non-LARC methods.    There were 5086 female residents of St. Louis participants, aged 14-45 
years, who were evaluated for their contraceptive method preferences by age.  All methods of 
reversible contraception were offered without cost to women for 3 years.  This study objective 
was to estimate the association of age and preference for LARC or other methods, and preference 
for specific LARC method among adolescents aged 14-20 years.  LARC methods were chosen 
by 70% (n=3557) of study participants, but among the adolescents age 14-20 years, 62% 
(658/1054) chose a LARC method.  Among 14-17-year-olds, 69% (148/214) chose a LARC 
method, whereas 61% (510/840) of 18-20-year-olds chose a LARC.  Of the LARC methods, a 
subcutaneous implant was preferred among the 14-17 year olds (63% or 93/148); however, 
selection of a subcutaneous implant device was only 29% (146/510) among 18-20-year-olds.  
This study concluded that LARCs are acceptable among adolescents enrolled in this project and 
the implant was the most popular method among the younger group.  




Fanarjian, Drostin, Garrett, & Montalvo (2012) conducted a retrospective cohort study to 
evaluate the effectiveness of free intrauterine contraceptives in reducing pregnancy rates among 
low-income women.  The study, conducted in two North Carolina clinics between January 1, 
2003 and June 30, 2009, included eligible uninsured women ages 15-44 years who desired 
contraception.  Pregnancy rates were studied between groups with the exposure (IUC users) and 
the unexposed group (non-IUC users).  Non-IUC users included women who chose to use other 
forms of contraception or no contraception at all.  The original sample size was 321 women; 
however, over the course of the 6.5 year study all but 90 were lost to follow up by either phone 
or mail.  A Levonorgestrel IUC was used in 65 participants; 25 non-users comprised the control 
group.  Seven pregnancies (11%) occurred in the user group; the IUC had been removed prior to 
pregnancy in all 7 subjects.  Of the 7 pregnancies in the user group, 3 were planned.  Eight 
pregnancies (8/25 or 32%) occurred in the non-IUC users.  Even though a small study sample 
due to the low response rate (32%) was the main restriction of the study, the final result showed 
no pregnancy per 100 women years in the IUC user group compared to 16.2 pregnancies per 100 
women for the unexposed group. 
Godfrey and colleagues (2010) investigated the effectiveness of LARCs in a multicenter, 
randomized, controlled pilot study (n=23) of 14-18-year-old females divided into groups who 
were randomized to receive a copper T 380A IUD or LNG-IUS.  At 6 months of follow up, the 
continuation rate for the levonorgestrel group was 75% compared with 45% for the copper T 
380A group (p = .15).  Among those participants at 6 months, 100% in the LNG-IUS group and 
83% in Copper T380A group planned to continue their IUC use after the study (p=.36).  Both 
methods were rated favorably by study participants, but there was a non-statistically significant 




lower continuation rate at 6-month follow up among the copper T 380A users.  The pilot study 
results warrant a larger scale study of IUD use among adolescents in the future.  
Short, Dallay, Omokanye, Hanisch, & Inki (2012) published an interim analysis report at 
the end of the first year of an observational study regarding the acceptability of levonorgestrel 
IUS (LNG-IUS) and etonogestrel implant (ENG implant) use among young European women, 
ages 20–35 years.  The study included 454 women from 4 countries (France, Ireland, Slovakia, 
and the United Kingdom) who opted to switch from oral contraception to either the LNG-IUS or 
the ENG implant.  At the planned interim analysis in September 2010, follow-up data had been 
obtained from 311 women out of the original 454.  Among 311 study subjects, there were 211 in 
the LNG-IUS group and 100 in the ENG implant group.  The continuation rates at 12-months 
were 93% for LNG-IUS and 86% for ENG implant.  At 1-year follow up, there were no 
pregnancies, pelvic inflammatory disease, perforations, or other complications recorded.  
Participants’ satisfaction was evaluated with a 5-degree Likert-like scale at the 12-month follow-
up visit or at discontinuation.  About 62% of LNG-IUS users were satisfied with their 
contraceptive method compared to 36% of the ENG implant users.  The difference in level of 
overall satisfaction between the two groups was statistically significant (p<0.001).  Most users 
were satisfied with their method of contraception after 1-year of follow-up.  The conclusion of 
the study showed that both the LNG-IUS and ENG implant are highly acceptable contraceptives 
among women, but the LNG-IUS users showed the highest continuation and satisfaction rates.  
A systematic review of the literature regarding IUD use among adolescents was 
conducted by Deans and Grimes (2009).  Six cohort studies and seven case-series were included, 
but none of the IUDs included in the study are currently in use in the United States.  Generally, 
the IUD has similar or better continuation rates when compared with combined oral 




contraceptives.  The cumulative pregnancy rate among IUD users was low, ranging from 2% at 6 
months to 11% at 48 months.  Even though the published studies show improved rates of IUC 
use in adolescents, the literature on IUC use among adolescents is sparse. Further randomized 
control trials and cohort studies are needed.   
Mansour (2012) also provided updated information of the risk and benefits associated 
with use of levonorgestrel IUS through a literature review.  Rapid fertility return after 
discontinued use is well established.  Even though transient menstrual disturbances during the 
first few months of use is typical, the condition will generally resolve itself with continuing use 
and the total amount of menstrual blood loss will also decrease.  Available data from the 
literature does not show adverse effects on bone health, cardiovascular events, breast, or uterine 
cancers, and it can be used by a wide range of populations.  
Overall, research demonstrates that IUCs are acceptable, safe, highly effective, and non-
user dependent.  The evidence strongly supports the integration of IUC services into primary-
care services, and student health clinics are ideal locations for the provision of IUC services. 
Evidence-Based Practice 
 Evidence-based practice involves the usage of quality studies as evidence to prevent 
errors in information, which will contribute to better clinical practice and quality patient care.  In 
order to identify the strengths and weaknesses of a research article and validate its findings, the 
critical appraisal process of a research study must be used to find the most relevant, high-quality 
studies (Young & Solomon, 2009).  In this project, the project leader independently completed 
the literature review process, which may lead to possible bias such as information selection 
bias.  The STROBE (Strengthening the Reporting Observational Studies in 




Epidemiology) criteria was used to evaluate observational studies, including cohort, case-control 
and cross-sectional studies (Young & Solomon, 2009) in hopes of assessing study quality and 
lessening study selection bias (Sanderson et al., 2007; von Elm et al., 2007) (see table 1 & 2 on 
page 85-89).   
Conceptual/Theoretical Framework 
Since the 1960s when the nurse practitioner (NP) role was developed, NPs have become 
increasingly important to serving as primary care providers who provide comprehensive services 
including health promotion, disease prevention, and counseling.   The 2010 Institute of Medicine 
(IOM) report The Future of Nursing: Leading Change, Advancing Health recommended that 
nurses should be providing health care services as fully as they were trained in their educational 
programs (IOM, 2011).  Following the implementation of the Affordable Care Act in 2010, more 
than 16 million individuals are projected to gain health insurance coverage by 2016. Combined 
with the rapidly aging population, NPs are increasing in demand as primary care providers.  An 
up-to-date literature review of NP practices by the National Governors Association (NGA) found 
that the quality of care provided by an NP and resultant patient health outcomes, is comparable 
to care provided by a physician (Schiff, 2012).   
NPs can serve successfully as primary care providers and can be differentiated from 
physician’s services as human caring is being blended into NPs scientific-based training and 
clinical practices (Hagedorn & Quinn, 2004).  Human Caring is depicted by the Chinese 
characters “關心”, and this topic was discussed in an article by Jean Watson during in 1970s.  
Human caring is essential in nursing practice, and this concept empowers nurses to ensure 
patient safety and better patient health outcomes.  The core concepts of Watson’s theory of 




human caring/caring science is derived from carative to caritas that was assembled and published 
by the Watson Caring Institute (2010).  Her carative factors are the basis for current nursing 
practices.  Watson’s human caring theory, such as caritas processes, also called caring practices, 
have been applied into daily clinical practice.  For example, human caring for others and for self 
is the first core concept that is based on the moral, ethical, and philosophical foundation of love 
and values.  Respect for the person, including clinical staff and patients, and commitment to 
protecting human dignity are all aspects of care provided to meet their needs, routines, and 
rituals.  Increasing awareness of presence to the humanism of self and others and caring for self, 
others, and environment are also core concepts of Watson’s human caring theory.    
As primary care providers, NPs meet the complex challenges of translating rapidly 
expanding knowledge into practice and function in a changing health care environment.  The NP 
Core Competencies emphasize independent and inter-professional practice, analytic skills for 
evaluating and providing evidence-based, patient centered care across settings, and advanced 
knowledge of the health care delivery system (NONPF, 2012).  The human caring theory is also 
essential for practice NPs to provide quality patient care, ensure patient safety, and empower 
patients to make informed decisions about their care.  This will improve patient’s self-care and 
health outcomes, and care for the environment.   
Methods 
Ethical issues 
As a health care provider with ethical obligations, one of the trademarks of 
professionalism is the responsibility to respect the clients’ interests above all else.  After 
reviewing the Belmont Reports, established in 1979 by the National Commission for the 




Protection of Human Subjects of Biomedical and Behavioral Research, the three general ethical 
principles, identified to the ethical conduct of research with humans, are also essential in daily 
clinical practice.    The first ethical principle is “Respect for persons,” the concept that a client’s 
autonomy must be acknowledged and each individual should participate in informed decision-
making of their own care.  The second principle is “Beneficence,” or “Do no harm,” meaning 
that providers should make decisions in order to maximize benefits while minimizing possible 
risks.  The third, “Justice,” requires that the patient is treated fairly, equally, and appropriately 
(Beauchamp & Childress, 2009).  These three general principles establish the foundation for the 
conduct of research; similarly, clinical practice principles are guided by informed consent, 
risk/benefits assessment, and care provided fairly.   
This quality improvement (QI) project for adding LARC services into primary care-
focused student health is based on the observational study of the current clinical services of 
women’s health care and contraceptive use by current students.  Prior to initiation of this project, 
the project proposal was approved by the DNP Department and Institutional Review Board 
approval (Appendix A-1 & A-2) was completed to ensure patients’ safety & privacy.   
Contraceptive use was evaluated by retrospective chart review from all women’s health related 
clinical visits without involving any demographic data of individual student identities to ensure 
patients’ privacy.  LARC protocol and informed consent have been completed and approved by 
the administrative committee as well as all providers to ensure patient’s safety in receiving 
LARC services. 
Also, addressing the misperceptions regarding the use of IUC among patients and health 
providers can facilitate smooth integration of IUC services into a primary care focused student 
health clinic.  The U.S. MEC is an essential tool that is useful to health care providers in the 




clinic to counsel female patients and couples on safe choices for contraceptive methods and to 
assist women with medical conditions understand their choices for contraception (U.S. MEC, 
2010).  Informed decisions made by patients in clinical practice will lead to better patient self-
care and health outcomes.  A consultation appointment to explain the mechanisms of the LARCs 
along with obtaining informed consent (see Appendix B) is essential to help patients & partners 
dispel their fears & misconceptions about the methods that they decide on.     
Setting 
Student Health and Counseling Services (SHCS) of California State University, East Bay 
(CSUEB) is an on-campus outpatient clinic accredited by the Accreditation Association of 
Ambulatory Health Care, Inc. (AAAHC), which offers mainly primary medical care to students 
and is staffed by three full-time and two part-time physicians, one full-time and one part-time 
nurse practitioner, two full-time registered nurses, one full-time licensed vocational nurse, and 
five full-time medical assistants.  There are also health promotion and counseling departments 
within SHCS that are staffed with many health educators and counselors.  There is a staffed 
pharmacy and laboratory on site. According to the 2011 Enrollment Headcount Report, there 
were 13,160 enrolled students composed of about 60% (7,959) female and 40% (5,201) male 
students with an average age of 26 (Baker et al., 2013).   
The mission of SHCS is to assist students in achieving their academic and career goals by 
providing resources to help them maintain optimal health, to provide high quality, low cost 
health care to all CSUEB students, and to be pioneers in the university health and wellness 
services.   
Planning the intervention 





To understand the current state of the need to provide LARC service, a SWOT analysis 
has been completed (see Appendix C).  Based on the SWOT analysis of the strengths of the 
project, one skilled staff nurse practitioner is able to consult, insert and follow up with students 
who have chosen a LARC method and will help train staff physicians and assist with their first 
few procedures.  Care is provided on campus at the SHS which is a convenient location for 
students.  There is no restriction per student on the number of clinical appointments, and students 
with concerns who wish to meet with a provider will be able to book the earliest appointment 
available by calling in or by self-booking online.   LARC methods are fully reimbursed by the 
Family Pact Program.  The SWOT analysis also point out weaknesses of the project.  Concerns 
center on the need to train three staff physicians on LARC use and follow up, and the expense of 
acquiring LARC devices before providing the service.  The third SWOT analysis, opportunities, 
indicates that there will be many opportunities to provide LARC services, as none of the other 
CSU campuses provide the services, the Planned Parenthood clinics and community health 
clinics where students used to be referred are all located off campus, and not all students have 
cars to visit clinics off campus.  To visit clinics off-campus is very time consuming to students.  
Also, staff physicians will gain new skills to serve patients.  Finally, to analyze threats to the 
project, the cost of each LARC unit is currently approximately $700 dollars.  Competition for 
services include Planned Parenthood Mar Monte which provides clinic services at their Central 
Hayward location, although with restricted hours, and the Community Health Care Network 
clinics, Women’s Clinic of Alameda County Medical Center, and private health clinics.  
Currently, SHCS does not accept any medical insurance; therefore, students who are interested in 




LARCs and not eligible for coverage by Family Pact program will need to seek care from their 
own primary care providers or pay out-of-pocket.        
Gantt chart 
The Gantt chart depicted in appendix D provides information about LARCs service 
project planning and monitors progress for tasks such as training providers, staff, meeting with 
the administrative team, and service launch.  The Gantt chart is posted on a Google drive file to 
share with all staff in the clinic. 
Critical Activities 
To ensure a safer patient care environment by preventing errors and mitigating the risk of 
causing harm to patients and staff, a clinical protocol and policy regarding the LARC procedure 
and medical errors also must be established.  Prior to starting the LARCs service, the potential 
risks of patient adverse outcomes needs to be carefully evaluated and precautions put in place to 
ensure the safest patient care at SHCS.  The Failure Modes and Effects Analysis (FMEA) or 
Failure Modes, Effects, and Criticality Analysis (FMECA) is a systematic, proactive method to 
investigate potential risks that focuses on identifying vulnerability and preventing future failures.  
FMECA focuses on system design and process rather than on a single incident such as in root-
cause analysis (IHI, 2004; Nagamine & Williams, 2005).  When doing a FMEA, we should 
include a review of the following steps in the process:  failure modes (what could go wrong?), 
failure causes (why would the failure happen?), and failure effects (what would be the 
consequences of each failure?) (IHI, 2004; Larson & Gray, 2011).  An example for this project is 
shown in Appendix E.  Every specific step in the process that can possibly go wrong is listed in 
the flowchart with the consensus of the group.  All possible causes are identified for each failure 




mode listed.  Next, the group is assigned a numeric value (known as the Risk Priority Number, or 
RPN) from 1 -10 for likelihood of occurrence, likelihood of detection, and severity.  Then, 
multiplying the three scores, we obtained the RPN for each failure mode.  Therefore, in order to 
focus improvement efforts on the most important area of the process, it is helpful to find out the 
failure modes with high RPNs. 
The activities have been evaluated for potential risks, which were included in a “things to 
look for” section during the presentation to the administrative team, and also reviewed while 
comprehensively training providers, keeping an updated list of supplies, tools, LARC units, and 
establishing an account with pharmaceutical companies for purchasing of LARC units.  An 
informed consent for patients and LARC protocols (appendix B-2 and B-3) are established and 
approved for the staff to use.  Advertising on campus is via text message, email, through the 
SHCS home page, and advertisements sent to other CSU campuses.  
Plan for Variance Control and Evaluation Criteria 
We use data collection forms (Appendix F) to collect information from scheduled 
women’s health related appointments by all providers.  To prevent errors and to make it easier to 
trace errors for correction, individual providers tally their data on the data collection form each 
week.  For providers who have missing data, the project leader follows up at the end of each data 
collection period.  Using data from the summer & fall quarter allow us to gain a perspective from 
a mixed student population. For example, there are more junior & senior students in summer 
quarter and more freshmen students in the fall quarter.   
Evaluation Criteria 




The forms used for data collection were made by the primary investigator based on the 
study inclusion criteria derived from the Female Medical History Form that is part of the 
recommended documentation by the Family Pact Program: age, history of pregnancy, sexual 
partners, method of contraceptive use, and length of usage (Family Pact, 2014).   
Before providing new medical services in the primary care clinic according to affordable 
care act (ACA) expectations, the primary care providers and internists must attend new training 
workshops.  County or local specialists contact information has been updated for consultation or 
referral as needed.  Annual refresher courses will be planned as needed depending on the amount 
of services provided.   
Risks Prevention 
A risk breakdown structure (RBS) (appendix G) is used to help identify risks from the 
macrosystem to microsystem that affect adding the new service in order to mitigate risks and 
prevent adverse events in advance (Larson, 2011).  The risks can be identified in four categories: 
technical, external, organizational, and project management.  The subcategories under technical 
risk include skills for the procedure, reliability and quality of the service.  The external risks 
include regulatory, policy and procedure, market, and customer.  Resources, funding and 
prioritization are considered under the category of organization.  For project management, 
estimating, planning, control, and communication are considered.       
Institutional Review Board (IRB) training and completion (see appendix H) is required 
by the Project leader to ensure human subject protection and to minimize risks from the study.  
No patients’ identities are included in the data processing or reports.   




An Ishikawa diagram (Appendix I) is used to help plan the project and identify potential 
risks that will affect the project (Nelson, Batalden, & Godfrey, 2007).  The diagram also is used 
for continuing evaluation of the project as it progresses, and updates will be provided and 
discussed during the weekly provider/staff meeting and monthly QI meeting.   
Implementation of the project 
 A retrospective review of electronic records from approximately 1000 clinical notes of 
all women’s health related visits during summer & fall quarter from June 24 to December 24, 
2013 has been completed.  The chart review and data collection was performed from December 
2013 through the end of January 2014.  A form with the necessary information and key criteria 
for study in Appendix F was developed during summer 2013 and was continuously revised 
throughout the fall quarter.   Data were analyzed by project leader in April 2014.  
An advertisement and marketing program is important and needed for this new service, 
including but not limited to text messages sent to students and emails broadcasting to other CSU 
campuses.   The nursing department is responsible for organizing the required supplies and 
instruments on the list provided by the Nurse Practitioner who also will continue to update the 
list as needed.  A meeting with the Clinic Director, the Administrative Analyst for purchasing 
LARC units was completed at the beginning of summer quarter 2014.  Students who are 
interested in LARCs will be required to have a consultation appointment prior to scheduling a 
LARC placement appointment, and these consultation appointments may be scheduled anytime 
per the student’s request.  The service was planned to be provided to students starting summer 
quarter 2014, but has been delayed to fall quarter because the procurement process is still 
pending and the summer quarter students’ health clinic coverage was changed by the university.   




A list has been established during the spring quarter and summer quarter for students who are 
interested in LARC and wished to be contacted when the service is available.  On October 20
th
, 
the nurse practitioner received a call from the pharmacist that one of LARC units, the 
contraceptive implant, has been approved to start.  A secure message was sent to individual 
students on the list regarding the approval of the service.    
Planning the study of the intervention 
Action Plan of LARC Services 
On college campuses, Student Health Clinics have the unique role of helping students 
maintain their optimal health which allows them to succeed in academic study, future career, and 
in life.  The majority of enrolled students are females between the ages of 18 and 24, and do not 
plan to conceive while they are pursuing their college education (ACHA-NCHA II, 2013).  
Preventive health services, including family planning and the provision of highly effective long-
acting reversible contraception, are essential and should be integrated into primary-care focused 
student health clinics.  To prepare for the integration of LARC services into primary-care 
focused Student Health Clinics, the action plan includes staff education, patient counseling, risk 
prevention, administrative issues, and establishment of equipment protocols (clinical minutes, 
ARHP, 2013).  The goals are to increase access to LARC services, empowering patients, 
improving efficiency, and improving staff knowledge. 
Staff education: Staff education is essential to integrating LARC services into the college 
student health clinics. This means new skills and scientific-based evidence for the primary care 
providers and internists who do not specialize in the area of women’s health care.  LARC 
placement and removal training is the first step.  Annual refresher courses to update skills and 




knowledge will be planned as needed depending on the amount of service provided (see Table 4 
provider training plan on page 87).  The U.S. MEC is an important resource for health care 
providers to counsel their patients and to help them make safe choices for contraceptive methods 
(US MEC, 2010).  Furthermore, nurse practitioners and health care providers also use the U.S. 
SPR as guidance for clinical contraceptive management to help reduce the unintended 
pregnancies rate among college students (US SPR, 2013).    
Patient education: Clinicians are providing individualized counseling for contraception 
choices, the efficacy, benefits, and side effects of method chosen (US MEC, 2010; US SPR; 
Hathaway, 2013), and utilizing the “Teach-Back” method to assess, teach, and confirm student’s 
understanding of the information (AHRQ, 2010; Moritsugu, 2006; Brach et al., 2012; White, 
Garbez, Carroll, Brinker, & Howie-Esquivel, 2013).  Clinicians must provide time for students to 
review and sign the Informed Consent Forms for the LARC procedure.  
Risk prevention: Policy and LARC clinical practice protocols have been established to 
help plan the services, to identify and mitigate potential risks, and to prevent negative outcomes.  
Patient selection criteria and contraindications according to the U.S. MEC for LARC method are 
included in LARC clinical protocols.   Any patient, whose desired LARC with U.S. MEC 3 and 
4 conditions will be excluded, so clinical protocols for consultation or referral to local specialists 
have been established.  Risks that have been addressed include ensuring that providers have the 
necessary skills, that standard of care is maintained, and that appropriate policies and 
communication channels are in place if any adverse incidents are to occur.   
Administrative issues: The administrative team has addressed the purchase of LARCs 
prior to beginning services.  In addition, an appointment policy has been developed.  On average, 




three appointments (consultation, insertion, and follow up) are needed for each patient.  A 
consultation appointment will be required from students who are interested in LARC prior to an 
LARC placement.  Billing and coding training have been completed for reimbursement of LARC 
services that included management of costs of all necessary health care services and supplies.  
Advertisement and marketing are also important when offering a new service.  To spread the 
word about services text messages and emails are employed.    
Equipment protocol: New instruments exclusively for LARC placement or removal have 
been requested and completed.  The Nursing Department is responsible for coordinating 
equipment inventory, organizing the required supplies, and ordering and restocking LARC 
devices.  The supplies include: miscellaneous supplies (clean gloves, sterilized gloves, betadine 
swab sticks package, sterilized gauze, long big cotton swabs, silver nitrate sticks, Maxi pads, and 
patient instruction), instruments (sterilized speculum, ring forceps, tenaculum, uterine sound, and 
long scissors), and LARC devices. 
LARC service evaluation: The program will be evaluated quarterly.  The following 
outcomes can be used to measure program progress & success - number of LARC consultations, 
number of LARC placements, continued contraception use, training progress, quarterly billing 
and reimbursement, and satisfaction of the services from patients and staff.  Students will be 
followed every 6 months by secure message system within their electronic record or by phone 
with electronic documentation until they graduate.   
A retrospective evaluation of LARC services to assess the success and long-term 
sustainability of the program is necessary. Off campus referral rates, adverse procedure incidents, 
infection rates, and staff and provider satisfaction regarding the process must be studied. 




Improvement measures for continuation of the service should be discussed monthly to assure that 
the best quality of care is delivered and patient safety is maximized at Student Health Services.  
Analysis  
 According to the ACHA-NCHA II Spring 2013 nationwide survey results, 64.4% of 
sexually active college students  used  hormonal contraceptives including oral contraceptive pills, 
patches, and rings; 3.4% received DMPA injection; 1.8% used contraceptive implant; and 6.9% 
used IUC.  The current usage of LARC among our students, who use a contraceptive method and 
have visited SHCS, is 1% for contraceptive implant and 3% for IUC (See Appendix J).  LARC 
usage by our students is much lower than the national benchmarks (see Table 1), which may be 
partially associated with the fact that the LARC services are not available in our SHCS. 
Results 
Description of Data: 
Records from all female university students who visited SHCS during summer and fall 
quarter 2013 for women’s health related care were reviewed.  All female students in any age, 
race, and ethnicity were included.  Electronic medical records of all visits and demographic 
information were reviewed and analyzed by the primary investigator from February to March 
2014.  A faculty member in the statistics department was a consultant for the on-campus study in 
the summer 2013.  A few of the female patients who were seeking care for women’s Health 
related issues were under age 18 at the time of study and their parental consents and clinic care 
consents for care were on file; otherwise, their records were excluded in this study.   




Evidence of Data Collection: the Primary Investigator conducted a chart review of 
clinical visits through the electronic health record (health history, medical record, lab report) at 
the beginning of 2014 at SHCS.  A data collection form (See Appendix F) that was developed 
during the summer quarter was used.  For the study, we tracked client data by electronic chart 
review based on the clinical visit notes during June 24 to December 20, 2013.  A retrospective 
review of 1031 subjective notes of all women’s health related visits during summer and fall 
quarter from June 24-December 20, 2013 was performed.  The chart review and data collection 
took place in January-February 2014.  A form with the necessary information for study was 
developed during summer 2013 has been used to tally the data.   Data were analyzed by the 
project leader.  The analysis was complete in April 2014.  (See Appendix J) 
Study Results:  After reviewing a total of 1031 visits electronically from June-December 
2013, the project leader found that most of our clients (71%) were 24 years-old or younger.  The 
contraceptives used by our clients were: 52% hormonal contraceptives, including oral 
contraceptive pills, patches, and rings; 7% DMPA injection; 1% contraceptive implant; and 3% 
IUC.  (See Appendix J) 
Program evaluation/Outcomes 
The program will be evaluated at the end of every academic quarter.  The following key 
performances will be used to measure program progress and success including number of LARC 
consultations, number of LARC placements, pregnancy rate, training progress, monthly financial 
reports, and satisfaction surveys from patients, providers, and staff.  Providers will follow up 
with patients every 6 months by secure message system or phone until they graduate.  A weekly 




update of project progress will uploaded to a google drive file to share with all providers and the 
QI committee, and a monthly report will be given at the all-staff meeting.   
By June 30, 2015, a retrospective study for this LARCs service will be held.  Besides the 
key service performances, the off campus referral rates, adverse procedure incidents, infection 
rates, and unintended pregnancy rates will be studied.  The final report will be delivered in QI 
committee meeting and the first all-staff meeting in the fall quarter.  Based on the study results, 
the improvement measures for the future service will be started during the weekly provider 
meetings during the fall quarter 2015 to assure the best quality of care is delivered and patient 
safety is maximized at SHCS.  
Discussion 
Summary 
Compared to the ACHA-NCHA II Spring 2013 nationwide survey results, LARCs usage 
by our students is much lower than the national benchmarks, which may be partially accounted 
for by the fact that the LARC services are not available in our SHCS.   
Potential benefits:  The study results will help to guide implementation and 
improvement of women’s Health services at SHCS.  Because this is based on a retroactive chart 
review, no compensation or other incentives will be provided to any of the students.   
Potential risks: Privacy and emotional discomfort (unrelated to the direct effects of the 
study) may be potential risks that will be felt by some students who visited SHCS during the 
time of the study.   




Risk reduction:  Any patient’s identifying information will not be used during the data 
collection and this helps to minimize the potential risks to any student included in the study.   
Risk/Benefit:  The potential risks to the subjects, such as privacy and emotional 
discomfort felt by some of the students who visited SHCS during the study period were not 
related to the direct effects of the study.   
Study limitation:  The study was conducted for the purpose of quality improvement at 
the on campus student health clinic of CSUEB, so the study demographic was limited only to 
students registered with CSUEB during the study period.  The results will help clinic services 
and quality improvement, but further study will be needed to determine the applicability to other 
colleges and student health clinics.   
Study unexpected benefit:  Improvements in clinical documentation for better service & 
care to the clinic patient is very important.  From the data collected, it was determined that about 
14% (143/1031) patients’ past obstetrics, gynecology, and sexual history information were 
missing (See study results, p32.).  This information is very pertinent history for women who are 
seeking contraceptive care.  The importance of this data will be emphasized throughout project 
implementation and improvements tracked. 
Barriers to implementation/Limitations:  Adding new patient services means that 
clinic providers must learn new skills or be able to perform a skill that they may not comfortable 
or familiar with. All of the providers in our clinic graduated from their medical schools or nurse 
practitioner programs over 15 – 20 years ago.  For seasoned clinical providers, learning new 
clinical skills can be a challenge, and the many misconceptions about LARC use and the 
notorious history of the Dalkon Shield IUD about 30 years ago are keeping both patients and 




providers at a distance.  Despite the safety and efficacy of modern LARC devices, dispelling 
misconceptions and rumors, training providers and staff, patient counseling and informed 
decision making with evidence-based information are all barriers that must be addressed prior to 
the effective integration of LARC services into primary care-focused student health clinics.  
Conclusions 
Unintended pregnancy is still a significant social issue that affects the quality of life for 
parents and their children.  Since the highest rates of unintended pregnancy occur in college age 
women, and about 80% of college women are sexually active without planning to become 
pregnant (Kavanaugh et al., 2012), it is very important to provide these women with effective 
contraceptive methods.  To help prevent unintended pregnancies, integrating LARC services into 
primary care-focused health clinics and student health services is necessary.  Provider training 
and patient counseling to dispel misconceptions regarding LARC use has been shown to improve 
usage and continuation rates of LARC contraception (Arrowsmith et al., 2012; Garber et al., 
2013).  To help young college aged women make an informed decision about contraception use, 
Nurse Practitioners and Medical Providers need to eliminate the misconceptions and provide 
evidence-based information to educate adolescents and young women about LARC methods and 
access.  All of these steps will help reduce unintended pregnancy, help to increase contraceptive 
use and adherence, promote healthy behaviors, decrease sexually transmitted infections, and 
increase access to the health care system.   
Other information: Provider Training and Funding 
Provider training 




This project was received very enthusiastically by the Student Health Center.  All full 
time and part time providers have attended the Nexplanon training session by Pharmaceutical 
company and have received Nexplanon certification.  All full time providers have also received 
training for Mirena insertion and removal.  1 Family Practice physician and 1 internist have 
completed training of Paraguard IUD, and they will continue onto the next steps of training – 
observation, supervised insertion, and supervised removal of all LARC devices.  Future training 
sessions for the remaining providers will be scheduled based on their availability (see Table 4 
Provider LARC training plan on page 87). 
Budget presentation 
   Direct costs for this project include providers, equipment, and supplies.  Providers include 
one nurse practitioner (1FTE), three physicians (3 FTEs), two part-time physicians (total of 0.4 
FTE), 7 FTEs of supporting staff including two registered nurses, and five medical assistants.  
The supply costs will cover miscellaneous supplies (clean gloves, sterilized gloves, Betadine 3-
swab package, 2x2 sterilized gauze, 3 ml syringe, injection needles, 1% Xylocaine injection 
solution, long cotton swabs, Maxipads, instruction handouts),  tools (5 of each—sterilized 
speculum, ring forceps, long kelly clamp, tenaculums, metal or plastic sounds, long scissors), 
and starter LARC units ( 5 of each ENG-Implant, Copper T 380A IUD, and LNG-IUS).  Indirect 
costs include 1 FTE center director, 2 FTEs administrative assistants, 4 FTEs front desk staff, 1 
FTE IT staff, 1 FTE housekeeping, 1 FTE health promotion staff, educational and advertising 
material, computer, office, etc.    
   A pre-paid package includes a total of fifteen LARCs units, or five of each type, which will 
costs about $11,000 plus $2,000 of supplies, for a total of $13,000.  On average, three 




appointments will be needed for each patient including one 30-min LARCs consultation, one 30-
min LARC placement, and a 15-min appointment for 2-month follow up after LARC placement.   
The medical assistant needs about15 minutes to set up the exam room and intake the patient.  A 
male provider will require a chaperone while performing the pelvic examination or procedure.   
   The cost of providing the LARC services to students at SHCS will be reimbursed by the 
Family Pact Program.  After consulting with the providers and staff at SHCS, all parties believe 
that providing this service is feasible and will be beneficial for both students and SHCS.  The 
funding for a few LARC units and the initial set-up are required in order to start the service.  
Budget projection for the pre-paid LARC units and reimbursement are estimated and outlined in 
Appendix K-1.  Since the Implant Contraceptive has been approved to purchase in October 2014, 
a budget projection for Implant Contraceptive service is estimated in Appendix K-2. 
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Appendix B-1.  LARC Informed Consent 
STUDENT HEALTH & COUNSELING SERVICES 
California State University, East Bay 
Hayward, California 94542-3060 
 
Informed Consent For NEXPLANON Placement or Removal 
A. Consent For Procedure(s) 
I authorize ______________________________________,MD/NP to perform the following procedure(s): 
NEXPLANON (etonogestrel implant) Radiopaque  Subdermal Use Only 
I have read and understand the Patient Information for NEXPLANON. I have discussed NEXPLANON 
with my healthcare provider who answered all my questions. I understand that there are benefits as well 
as risks with using NEXPLANON. I understand that there are other birth control methods and that each 
has its own benefits and risks. 
I also understand that this Patient Consent Form is important. I understand that I need to sign this form to 
show that I am making an informed and careful decision to use NEXPLANON, and that I have read and 
understand the following points. 
 NEXPLANON helps to keep me from getting pregnant. 
 No contraceptive method is 100% effective, including NEXPLANON. 
 NEXPLANON has an implant that contains a hormone. 
 It is important to have the NEXPLANON implant placed in my arm at the right time of my 
menstrual cycle. 
 After the implant is placed in my arm, I should check that it is in place by gently pressing 
my fingertips over the skin where the implant was placed. I should be able to feel the 
implant. 
 The implant must be removed at the end of three years. The implant can be removed sooner if I 
want. 
 If I have trouble finding a healthcare provider to remove the implant, I can call 1-877-467-5266 
for help. 
 The implant is placed under the skin of my arm during a procedure done in my healthcare 
provider’s office. There is a slight risk of getting a scar or an infection from this procedure. 
 Removal is usually a minor procedure. Sometimes, removal may be more difficult. Special 
procedures, including surgery in the hospital, may be needed. Difficult removals may cause 
pain and scarring and may result in injury to nerves and blood vessels. If the implant is not 
removed, its effects may continue. 
 Most women have changes in their menstrual bleeding patterns while using 
NEXPLANON. I also will likely have changes in my menstrual bleeding pattern while 




using NEXPLANON. My bleeding may be irregular, lighter or heavier, or my bleeding 
may completely stop. If I think I am pregnant, I should contact my healthcare provider as 
soon as possible. 
 I understand the warning signs for problems with NEXPLANON. I should seek medical 
attention if any warning signs appear. 
 I should tell all my healthcare providers that I am using NEXPLANON. 
 I need to have a medical checkup regularly and at any time I am having problems. 
 NEXPLANON does not protect me from HIV infection (AIDS) or any other sexually 
transmitted diseases. After learning about NEXPLANON, I choose to use NEXPLANON. 
B. Consent For Anesthesia 
When local anesthesia is used for NEXPLANON placement or removal by the MD/NP on page one, 
Section A: 
I consent to the administration of such local anesthesia, 1% LIDOCAINE without Epinephrine as may 
be considered necessary by the MD/NP in charge of my care.  I understand that the risks of local 
anesthesia include: local discomfort, swelling, bruising, allergic reaction to medications, and seizures. 
C. Patient Signature: 
After learning about NEXPLANON, I choose to use or remove a NEXPLANON on my right/left upper 
arm.  By signing below I state that I have read or had explained to me the contents of this form and I 
agree to receive the care, treatment or service listed on this consent.  I have had a chance to ask questions 
and all of my questions have been answered. 
    
(Name of patient)                (Student ID) 
    
(Patient Signature)        (Date) 
D. Physician or Nurse Practitioner Statement/Signature & Witness Signature: 
I have explained the procedure(s) stated on this form, including the possible risks, complications, 
alternative treatments (including non-treatment) and anticipated results to the patient and/or her 
representative.  The patient and/or their representative has communicated to me that they understand the 
contents of this form. The patient above has signed this consent in my presence after I counseled her and 
answered her questions. 
     
(Signature of MD or NP)                    (Date & Time) 
     
(Signature of Witness)                 (Date & Time) 




Appendix B-2  Protocols 
STUDENT HEALTH & COUNSELING SERVICES 
California State University, East Bay 
Hayward, California 94542-3060 
 
Protocol For Contraceptive Implant (Nexplanon) 
Definition: 
The ENG-Implant is a thin rod 4 cm long and 2 mm in diameter and contains 68 mg 
etonogestrel that is placed in the subdermal tissue of the inner upper non-dominant arm.  The 
ENG-Implant provides effective contraception, decreases menstrual blood loss, and painful 
menstrual cycles for at least 3 years.  The effectiveness of ENG implant to prevent pregnancy is 
greater than 99%.
9,10
 The mechanisms for contraception are changing endometrium tissue and 
changing cervical mucus to prevent fertilization.   
Many women prefer the convenience and efficacy of implantable progestin-only method.  A 
woman who experiences unacceptable estrogen-related side effects or who has contraindications 
to estrogen-containing contraceptive methods may be to use progestin-only birth control methods 
successfully.  Progestin-only methods may be preferred to combination hormonal methods for 
women with chloasma, hypertension, VTE, severe headaches, chronic asymptomatic hepatic 
disease, breastfeeding, tobacco use and age > 35 with a BMI greater than 30.  The typical use 
first year failure rates for progestin-only implants are at least as low as sterilization and with 
correct and consistent use may be as low as 0.1% and are not affected by obesity.  Progestin-only 
implants are often more popular among adolescent women.  It is likely that all progestin-only 
methods reduce the risk of endometrial cancer, especially in anovulatory women.  Several 
studies have reported that structured counseling, especially about longer acting methods may be 
very useful in helping women choose more effective methods and maximize continuation rates. 
 
Personnel:  
Subjective:    
          Must include:   
1. LNMP and PMP.  
2. Medical, sexual and contraceptive history (initial or update). 
3. Evaluation for allergies to any component of the method or to antiseptic or 
local anesthesia, if considering implant. 
4. History of any recent unprotected intercourse. 
   
          Must exclude:  
    Any US MEC Category 4 and 3 conditions for her desired method.  
 
Note:  Breastfeeding women can initiate any systemic progestin-only method 
immediately postpartum, despite labeling recommendations, as long as the women 
can tolerate a slight increase in lochial blood loss.  There is no increase in 
postpartum depression due to progestin-only methods. 
 
Objective: 




          Must include: 
1. BP. 
2. Weight, BMI (obesity is not a contraindication to any progestin-only method.  
The efficacy of implants and injections is not affected by patient weight.) 
Note:  Progestin-only methods may be initiated or restarted without pelvic 
examination in asymptomatic women who have not had recent exams.  Routine STI 
testing may be performed using urine or self vaginal swab specimens, if indicated. 
 
Laboratory: 
          Must include: 
Negative sensitive urine pregnancy test (UCG) only if patient has unexplained 
irregular or delayed menses or symptoms of pregnancy.  Routine pregnancy testing 
is unwarranted.  There may be more need to document that pregnancy has been 
ruled out for implant candidate seeking placement at unconventional times.    
 
Assessment:   
          Candidate for systemic progestin-only hormonal method. 
 
Plan: 
1. Refer patient if any US MEC category 3 and 4 conditions for desired method. 
2. If implant selected, place only if confident patient is not pregnant: 
a. No backup method is needed if implant placed at any of the following times: 
1) During first 5 days of menses. 
2) At any time if switching from combined hormonal contraception, 
include hormone free intervals of COCs, patch, or vaginal ring. 
3) At any time if switching immediately from progestin-only method, 
including progestin-only pills, DMPA injection, LNG-IUD or implant. 
4) If exclusively breastfeeding, and amenorrheic in the first 6 months 
following delivery, may place immediately if no recent unprotected 
intercourse. 
5) Within 5 days of first trimester pregnancy loss. 
6) Within 28 days after second or third trimester pregnancy loss or 
delivery.  
b. If placing at any other time, confirm pregnancy test negative, provide EC, if 
needed, and advise abstinence or provide barrier method for 7 days after 
implant placement. 
c. If placing this visit:  
1) Explain risks and benefits of implants.  Counsel about bleeding changes 
that may be expected. 
2) Obtain informed consent using SHCS consent form for implant 
contraceptive (Nexplanon) that includes all the information found in 
FDA-approved form. 
3) Place implant according to manufacturer’s instructions. 
4) Verify placement of implant. 
5) Provide post-placement instructions and precautions.  Advise abstinence 
or back-up contraception for 7 days, if needed. 




6) Document a placement procedure note. 
d. Have patient return for annual examination and PRN problems. 
  
Patient Education: 
1. Remind the patient that this method of contraception is safer for her health than 
pregnancy would be. 
2. Advise women that progestin-only methods do not protect against STIs, 
including HIV.  Recommend safer sex practices if patient is at risk for STIs.   
3. For Implant: 
a. Inform patient that she should: 
1) Keep the pressure dressing on for 24 hours. 
2) The steri-strips can be taken off in 3-5 days, although it is better to wait 
until they fall off by themselves.  Steri-strips should not be removed by 
patient until scab over the placement site had fallen off. 
3) If her arm is sore, she may also take Tylenol or Ibuprofen for the 
discomfort or place ice packs (20 minutes an hour) as needed. 
b. Advise patient to expect slight bruising and soreness around implant site for 
a few days after placement, and that the implant may be slightly visible 
after healing. 
c. Advise patient to watch for these rare warning signs and seek medical care 
promptly if any of the following appears: 
1) Bleeding from the placement site. 
2) Increasing tenderness, redness, warmth or pus around the implant. 
3) Fever, chills. 
4) Any sign that the implant is being expelled. 
d. Advise patient that protection from pregnancy begins immediately if 
placement is timed according to manufacturer’s recommendation.  
Otherwise she should not rely on the implant for 7 days after placement. 
e. Advise patient that bleeding may be less predictable with implant use.  
Over time, she will usually have less bleeding. 
1) Counsel her that if her bleeding is acceptable in the first 3 months, she 
can expect that following cycles will be acceptable. 
2) If her first 3 cycles are abnormal, tell her that she has a 50% chance that 
her bleeding will improve in subsequent months.  The time between 
periods may vary and she may have spotting in between periods. 
3) Suggest she keep a menstrual calendar and carry a light day panty liner 
with her. 
f. Remind her to use back up methods if she starts using any St. John’s Wort 
or prescription drugs that can reduce the effectiveness of her implant. 
g. Counsel patient that there is no harm to her health if she misses her periods, 
but instruct her to return for pregnancy testing if she has any symptoms of 
pregnancy or is concerned about the possibility of pregnancy.   
h. Advise patient of possible weight changes and other potential side effects 
including headache, mood swings, hair changes, prolonged ovarian cysts 
and other effects listed on package insert.  




1) Remind her that most of those “side effects” are not due to the implant.  
For example, in a trial comparing the implant with non-hormonal IUD, 
both groups of women gained the same amount of weight.  
i. Advise her to always mention her implant whenever she is seen by medical 
personnel/clinician.   
j. Remind her that the implant is effective for 3 years.  Tell her she will be 
given a user card that will remind her of this date.  Remind her that she is to 
keep the card in a secure place.  Advise patient that a new implant may be 
placed in 3 years if desired.   
k. Counsel her that fertility returns promptly after removal of her implant.   
l. Advise patient that she may request to have her implant removed at any 
time for any reason.   
m. Encourage patient to return for routine well woman exams. 
 
Referral: 
1. Any patient with US MEC category 3 and 4 conditions for this method she 
desires to use. 
2. Patient who declines pelvic examination but has symptoms or signs indicating 
need for evaluation.   
3. Patient with a difficult implant removal.   
4. Patient with anaphylactic shock with the procedure. 
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Summary of recommendation for Implant method initiation and management 
  
 
Initiating Implant Use Number of Days Back-up 
Method or abstinence 
Needed 
EC Need If Any 
Unprotected Coitus in Last 
5 days* 
   
Starting cycle day 1 – 5 0 No 
During hormone free 
interval of OCs, patch or 
vaginal ring 
  
At any time with progestin-
only pills 
0 No 
At time next DMPA 
injection is due (up to 15 
weeks from last injection) 
0 No 
At time of implant or IUD 
removal 
0 No 
Within 5 days of first 
trimester pregnancy loss 
0 No 
Within 28 days after 2
nd
 
trimester pregnancy loss 
7 Yes 





Exclusively breastfeeding in 
the first six months and 
amenorrheic with no 
unprotected intercourse 
0 No 
Placement at any other time 7 Yes 
 
 If unprotected intercourse in last 5 days, consider repeat pregnancy test in 3 


















Appendix B-3:  Protocol 
STUDENT HEALTH & COUNSELING SERVICES 
California State University, East Bay 
Hayward, California 94542-3060 
 
Protocol For Intrauterine Device (IUD) 
Definition: 
Intrauterine contraceptive (IUC) is a small device placed in the uterus to prevent 
pregnancy.  Currently there are three FDA approved intrauterine devices (IUDs) available in the 
US.  The Copper T-380A IUD (ParaGard®) is effective for at least 10 years.  In typical use, the 
copper IUD has a first year failure rate of 0.8%; its 10 years cumulative failure rate is 2.7%.   
The Levonogestrel intrauterine systems (LNG-IUS)–20 mcg/24 hr ( Mirena® ) is effective for 5 
years and has a first year and 5 year failure rate in typical use of less than 1%.  Mirena offers 
many non-contraceptive health benefits related to menstrual suppression.  The LNG-IUS-13.5 
mg (Skyla®) is approved for up to 3 years of use.  First year failure rate is 0.41%.  IUDs may be 
used by nulliparous women. 
 
Personnel:  
Physician and Nurse Practitioner/Certified Nurse Midwife with demonstrated skill under 
supervision of experienced clinician and/or experience with IUD insertion and removal can place 
or remove IUDs. 
 
Identification of Candidate: 
The U.S. Medical Eligibility Criteria (US MEC) are used as a basis for recommendations 
for this protocol. 
 
Subjective:    
          Must include:   
1. LNMP and PMP.  
2. Document any unprotected coitus in last 5 days. 
   
          Must exclude:  
    Any US MEC Category 4 and 3 conditions for her desired IUD.  
 
Objective: 
          Must include: 
1. Normal pelvic exam (Bimanual and speculum exams).   
2. Complete uterine involution (after 6 weeks postpartum) is needed following 
pregnancy. 
3. Patient’s uterine size on bimanual exam must be consistent with a uterine depth 
of: 
a. ParaGard: 6.0-9.0 cm. 




b. Mirena: 6.0-10 cm. 
c. Skyla: large enough to accommodate IUD, generally 6-10cm best.  
 
           Must exclude: 
  Any US MEC Category 4 and 3 conditions for her desired IUD. 
 
Laboratory: 
          Must include: 
1. Hgb/Hct if recent history of excessive menstrual blood loss or anemia. 
2. Patient does not need any testing done to qualify for IUD if she has no signs or 
symptoms of infection.  If indicated by age, screening guidelines, sexual history 
or symptoms, perform needed tests to rule out GC or Chlamydia cervicitis or 
Trichomonas vaginitis.  It is not necessary to delay IUD placement until results 
are available.  Prompt (within 7 days) treatment will prevent PID if the woman 
does have a cervical infection at the time of IUD placement. 
3. Negative pregnancy test if patient has had any unprotected intercourse at any 
time in her cycle that could result in pregnancy, or if she has had any irregular 
menses recently or any symptoms of pregnancy. 
 
          Must exclude: 
  Any US MEC Category 4 and 3 conditions for her desired IUD. 
 
Assessment:  Candidate for IUC/IUD use. 
 
Plan: 
3. Select IUD.  If patient has copper allergy, Wilson’s disease, anemia (Hgb less 
than 10 g/dL), excessive menstrual bleeding or severe dysmenorrhea, she is a 
better candidate for a LNG-IUS rather than for the copper IUD. If she prefers 
monthly bleeding or does not want to use hormones, ParaGard® would be a 
better choice.   
4. Instruct patient to read and answer all questions on patient product information 
brochure. Answer all of patient’s questions.  Have her sign the manufacturer’s 
consent form and any clinic consent form required. See manufacturer’s website 
to get additional copies of the patient brochure and the consent forms in her 
language. Tell the woman who wants to use one of the LNG-IUSs that she will 
have to sign another copy of the consent form for her particular IUS after the 
procedure is done.   
5. Consider advising patient to take a nonsteroidal anti-inflammatory agent 1 to 4 
hours prior to IUD/IUS placement if not medically contraindicated. It will not 
reduce pain during IUD placement, but may reduce cramping and pain 
afterwards.   
6. If possible, place the IUD at this visit (See IUD Placement protocol). If IUD not 
placed during this visit, insure she has an interim birth control method and tell 
patient when to return for placement according to the type of IUD she desires. 
7. Schedule Copper IUD (ParaGard®) placement any time in the cycle when the 
woman is not pregnant.   




a. Placement after completion of menses may reduce early expulsion risk. If 
possible, avoid placing IUD during heavy menstrual flow days. 
b. Copper IUD is effective as post-coital emergency contraceptive for up to 7 
days after exposure. 
c. May place a new IUD (copper or hormonal one) immediately after removing 
an existing IUD, if she is a candidate for her desired new IUD. 
d. Postpartum women will wait for an IUD placement until uterine involution 
is complete (usually 6-8 weeks). 
 
8. Schedule a levonorgestrel IUS (Mirena or Skyla®) placement according to the 
following instructions for on-label placement: 
a. Within first 7 days of cycle. To reduce early expulsion rates, try to avoid 
placement on heavy flow days. 
b. Women who are not cycling (e.g. due to breast-feeding or DMPA-induced 
amenorrhea) may have placement at any time they are not pregnant and 
have not had recent unprotected intercourse. Advise 7 days use of 
abstinence or back-up method after IUS placement. 
c. Women switching from OCs, advise completion of pill pack, especially if 
IUS is placed during the last week of active pills. 
d. May place new IUS immediately after removal of existing IUS if she is still 
a candidate. Removal is recommended on menses but if removed at other 
time in cycle, advise 7 days of abstinence or use of a backup method 
following replacement. Consider EC if she has had recent intercourse. 
Neither LNG-IUS is a post coital contraceptive. 
e. Placement of an IUS for postpartum women should probably be after uterine 
involution is complete (usually 6-8 weeks). 
f. If placement is desired at any other time in cycle or under different 
conditions, make sure the patient is not pregnant and have her use 
abstinence or a back-up method for 7 days following IUS placement. 
           
 
Patient Education: 
1. Reinforce IUD education as described in manufacturer’s brochure. Provide 
information about mechanisms of IUD/IUS action, stress the importance of safer 
sex practices, describe possible placement complications, and schedule follow-up 
as needed if problems arise after placement. Reassure patient that as an ongoing 
method, all IUDs work as contraceptives by preventing fertilization.   
2. Discuss risks of IUD/IUS if pregnancy occurs: ectopic pregnancy; preterm labor; 
need for IUD removal if possible; intrauterine levonorgestrel exposure (Mirena 
and Skyla®).   
3. Inform patient that Mirena is the most effective medical treatment for heavy 
menstrual bleeding, can reduce symptoms of endometriosis and problems with 
anemia. By providing progestin, Mirena® also helps reduce the risk of 
endometrial cancer and precancer, especially in women with anovulatory cycles.   




4. Discuss the expected short term side effects following placement, including 
unscheduled bleeding and cramping. Advise that many of these symptoms may 
subside over time.   
5. Discuss the intermediate and longer term effects of each IUD. 
a. ParaGard: Monthly bleeding will increase by an average of 30-50%, but 
that increase can usually be reversed by the use of NSAIDs during menses. 
b. Mirena:  
1) Unscheduled bleeding and spotting may be frequent in the first 4 
months of use, but will diminish over time. 
2) Total blood loss will be significantly reduced with longer use of Mirena. 
3) 20% of women will have no spotting or bleeding at all by 12 months of 
use. By that time, most other women will have only 1-3 days of spotting 
a month. 
4) Some women experience headaches or breast tenderness, especially 
with early use, but usually the symptoms are only temporary or are due 
to other causes. 
5) Mirena is the most effective medical therapy for heavy or prolonged 
menstrual bleeding. It may also help reduce dysmenorrhea. 
c. Skyla: 
1) Unscheduled bleeding and spotting may be frequent in the first 4 
months of use, but will diminish over time. 
2) Total blood loss will be significantly reduced with longer use. 
3) 12% of women will have no spotting or bleeding at all by 3 years of 
use. 
4) Some women experience headaches or breast tenderness, especially 
with early use, but usually the symptoms are only temporary or are due 
to other causes. 
6. Remind women that the pregnancy protection, non-contraceptive benefits and the 
side effects disappear almost immediately following IUD removal.  
 
Referral: 
1. Any patient with US MEC category 3 and 4 conditions to IUD she desires to use.   
2. Any patient who will need antibiotic prophylaxis for IUD placement.   
3. Refer women desiring IUD with labile or uncontrolled hypertension. 
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Treatment Guidelines. Available at http://www.cdc.gov/STD/treatment/   
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http://www.glowm.com/?p=glowm.cml/section_view&articleid=393.   
14. Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine 
contraceptive systems: a randomized controlled trial. Obstet Gynecol. 
2013;122(6):1205-13.   
15. ParaGard website: http://www.paragard.com/hcp/resources-for-your-patients.    
16. Sivin J. Utility and drawbacks of continuous use of a copper IUD for 20 years 
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17. Wiebe ER, et al. Motivation and experience of nulliparous women using intrauterine 
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Intrauterine Device (IUD) Placement: 
 
Definition: 
This protocol outlines the steps needed to reconfirm that the patient is a candidate for the 
intrauterine device (IUD) she desires and the steps to be followed in placing that IUD.  
Whenever possible, IUD placement should be done at the initial visit to reduce barriers to access 
and unintended pregnancy.  Practice with plastic models helps reduce complications (especially 
uterine perforation). 
 
Subjective:   
Must include:  
1. LNMP and PMP.   




2. Patient previously assessed to be eligible for IUD use according to 
Identification of Intrauterine Contraceptive Candidate protocol and 
desires IUD placement after reading product consent form.   
3. Medical and sexual history update with special attention to reconfirm IUD 
candidacy.   
4. No symptoms of pregnancy.   
5. Reconfirm that this is an appropriate time for IUD placement.   
 
Must exclude:   
 Any US MEC Category 4 or 3 conditions for her desired IUD.  
Objective: 
  Must include: 
1. Blood pressure > 140/90, provide alternate method and refer to off campus 
clinic for the IUD service. 
2. If placing IUD in absence of recent pregnancy, must have normal pelvic 
examination on day of placement demonstrating each of the following:   
a. Complete uterine involution.   
b. No sign of current vaginal or cervical infection.   
c. No signs of pregnancy.   
 
Must exclude: 
 Any US MEC Category 4 condition or 3 conditions for her desired IUD. 
Laboratory: 
 No Routine laboratory tests needed for IUD placement, except pregnancy 
test if patient at risk. 
 
Must exclude: 
 Any laboratory results indicating a US MEC Category 4 or 3 conditions for 
her desired IUD, such as current cervicitis, etc.  
Assessment: 
               Candidate for placement of intrauterine contraceptive. 
Plan:   
1. Review patient product information brochure with patient, answer all her 
questions, obtain her informed consent and have her sign all appropriate forms. 
Place forms into patient’s record.  
2. Premedication has not been found to decrease discomfort of IUD placement, but 
may be indicated in the following situations:   
 NSAIDs (Ibuprofen 400-600mg orally every 6 hours) to reduce cramping 
after placement.   
3. If patient found to have BV, treat with systemic not topical antibiotics. No need 
to delay IUD placement, but reinforce the importance of taking her antibiotics.   
4. If no recent pregnancy, place IUD according to manufacturer’s instructions with 
close attention to aseptic technique. Important elements include:  
a. Gently place tenaculum on the portion of the cervical lip that is 
further away from introitus (e.g. posterior lip with anteverted 




uterus) to straighten axis of uterus and to stabilize uterus. Apply 
traction on tenaculum to reduce risk of perforation. 
b. Careful uterine sounding to confirm that patient is candidate for 
her desired IUD.   
1) ParaGard 6.0-9.0 cm.   
2) Mirena 6.0-10.0 cm.   
3) Skyla – no dimensions set, but generally 6-10cm best.  
c. Open IUD package, load IUD and place IUD following 
manufacturer’s instructions.   
d. Trim tailstrings to fit around cervix.   
5. Write procedure note which records uterine position and size, depth of uterine 
sounding, depth to which IUD placed, and length to which the tailstrings 
trimmed, how well the patient tolerated the procedure, as well as any 
complications that may have been encountered during the procedure. Document 
IUD type, lot number and expiration date.   
6. Instruct patient to return to clinic for routine well woman care and earlier PRN 
problems with her IUD. No routine post-placement visit needed.    
7. Provide backup method for 7 days is LNG IUS placed at any time other than 
specified (e.g., within 7 days of LMP, delivery or at time of hormonal method 
change).    
8. Unless patient has contraindications to use of NSAIDs, advise use PRN problem 
with cramping or bleeding. Typical recommendation: Ibuprofen 400-600 mg 
orally every 6 hours when needed for cramping or heavy bleeding. Other 
NSAIDs at equivalent doses may be used.      
9. If patient has BP ≥140/90 verified at least one additional time in clinic with no 
smoking or caffeine for 30 minutes, refer for evaluation of possible 
hypertension.    
 
Patient Education: 
1. Reinforce IUD education, including checking strings monthly, signs and 
symptoms of possible IUD complications (e.g. infection, expulsion, 
perforation, pregnancy).   
2. Instruct patient to seek care urgently if any symptoms of PID, pregnancy or 
expulsion or if she experiences heavy vaginal bleeding or severe cramping.   
3. Instruct patient to return for re-evaluation of appropriateness of method if she 
becomes at risk for PID.   
4. Instruct patient with ParaGard that IUD removal is recommended on label by 
10 years, but that the actual length of use may be longer. On label the Mirena 
should be changed every 5 years, but new information may change that 
recommendation in the future. Skyla is approved for up to 3 years of use.   
5. Encourage routine health care.    
 
Referral:  
1. Any patient who has difficult placement.   
2. Any patient with elevated blood pressure or US MEC category 3 or 4 conditions 




3. Patient who presents for LNG IUS insertion at times in her cycle not specified 
on product labeling. 
4. Any patient who has history of any complication of IUD placement. 
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Definition:  Steps to follow in removing a patient’s Intrauterine Device (IUD). 
 
Subjective:  
        Must include: 
1. NMP and PMP.   
2. Medical and sexual history update.   
3. History of any recent intercourse, if patient not currently menstruating (may 
want to delay removal if recent exposure).    
4. Documentation of reason for IUD removal request.    
5. If patient wants to continue IUD use, but is requesting removal because her 
IUD has been in place for the number of years for which it is recommended, 
refer patient to off campus clinics such as Planned Parenthood Clinic or 
Community Health Center for the service. 
 





         Must exclude:  BP > 140/90 
         Must include: 
1. BP<140/90  
2. Pelvic examination—Check for any signs of infection or incorrect IUD 
placement.   
 
Laboratory: 
         Must include:  
1. Hgb/Hct (if history of excessive bleeding).  
2. Negative sensitive pregnancy test. 
 
Assessment:   
        Candidate for IUD removal. 
 
Plan: 
1. If IUD strings visible: 
a. Obtain patient’s informed consent for IUD removal acknowledging the 
risks of bleeding, pain, infection and failure to remove. 
b. If there are any signs or symptoms of cervical infection or PID, provide 
appropriate systemic antibiotics and administer first dose prior to removal.   
c. If the patient required antibiotic prophylaxis against endocarditis by AHA 
guidelines when she had her IUD placed, refer this patient to off campus 
clinic for IUD service.   
d. Remove IUD following manufacturer’s instructions. 
e. For postmenopausal women with stenotic os, refer this patient to off 
campus clinic for IUD service.   
2. If IUD string(s) are missing or break during removal attempt, refer patient to 
off campus clinic for IUD service. 
3. If IUD has been in place for more than 5 years or if patient has been 
experiencing any signs or symptoms of upper tract infection (e.g., vaginal 
discharge or lower abdominal pain), refer patient to off campus clinic for care 
& IUD service.    
4. If patient seeking pregnancy, provide preconceptional counseling.    
5. If patient desires contraception: 
a. If patient has re-qualified for an IUD, do not remove IUD and refer patient 
to an off campus clinic for IUD service.   
b. If patient desires another method, provide it.   
6. If patient has had intercourse in the last five days and is at risk for pregnancy 
if IUD removed, offer emergency contraception or delay removal of IUD.   
7. If patient with no prior history of hypertension has BP ≥ 140/90 verified at 
least one additional time this visit with no smoking or caffeine for 30 minutes,   
refer for evaluation of possible hypertension.   
 
Patient Education:  




1. Counsel regarding risk of pregnancy or ectopic pregnancy if IUD removed in 
absence of menses with recent intercourse; tell patient IUD no longer protects 
her from pregnancy.  Encourage EC use.     
2. Encourage women desire IUD removal in order to become pregnant to take 
folic acid supplement for at least 1 – 3 months prior to removal or at least to 
conception.   
3. Advise women who have IUD removed but are not seeking pregnancy to 
immediately initiate another effective method.  Remind them that the IUD 
provides no residual contraceptive protection once it is removed.   
 
Referral:   
1. Patient who requires antibiotic prophylaxis for prevention of endocarditis.   
2. A patient with elevated BP or difficult IUD removal. 
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2. Centers for Disease Control and Prevention. U.S. medical eligibility criteria  
      for contraceptive use, 2010. MMWR. Morb Mortal Wkly Rep. 2010;59:1-6.  
      Available at http//www.cdc.gov/mmwr/preview/mmwrhtm/rr59e0528al/htm.     
3. Centers for Disease Control and Prevention (CDC). US Selected Practice  
      Recommendations for Contraceptive Use, 2013 MMWR Recomm Rep  
      1013;62:1-60.    
4. Hatcher RA, et al (editors).Contraceptive Technology 20th edition Ardent  
      Media. New York, NY 2011:147-92.   
5. Hou SP, Chen OJ, Huang LH, et al. Medical methods for cervical ripening  
      before the removal of intrauterine devices in postmenopausal women: a  
      systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):130-42.   
6. Nelson AL. Intrauterine contraceptives. Glob.libr.women’s med., Available at:  
      http://www.glowm.com/   
7. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20  
      years. Contraception. 2007;75(6 Suppl):S70-5.   
  





List of supplies for IUC procedure:  
 
All lab results – Pap/GC/ CT 
Consent form for Paraguard or Mirena 
Ibuprofen (600 – 800 mg) 
Speculum  
Cotton swab (a bunch in a basin or a small basket) 
Betadine swabs (3) 
Tenaculum 
Sound (plastic or metal) 
IUC – Paraguard or Mirena 
Sterile gloves 
Scissors 
Silver Nitrate or Monsel solution 
Maxi Pads 
IUC information card 
Slip for f/u appt (after  first menstrual period) 
Smelling salt 
 
   




Appedix B-4:   NEXPLANON –SOAP template  
S:    LNMP:_______________  PMP:________________ Current Contraceptive:__________________ 
Last Pap:________________  Last CT/GC test:___________________  G___ P___ Tab___ Sab___ 
I. Absolute Contraindications:   None  /Other: 
1. Known or suspect pregnancy 
2. Current or past history of DVT/PE 
3. Liver tumors/active liver disease 
4. Hypersensitivity to any component of NEXPLANON 
5. Undiagnosed vaginal bleeding 
6. Current or past history of breast cancer 
7. Lupus 
8. < 4 weeks postpartum 
II. Relative Contraindications:  None  /Other: 
1. HIV+ / immunosuppressed 
2. Ischemic heart disease or stroke history 
3. Desired pregnancy before 1 year 
4. WT > 30% BMI 
III. Risk Factors for STD’s’:  None  /Other: 
1. Multiple partners 
2. High risk partner (multiple partners, injection drugs, HIV risk) 
3. Increased risk HIV  
O:        No Exam 
1.  See previous pap / other lab results 
2.  Pregnancy test result:  Negative / Positive  (Date:       ) 
3.  Pelvic Exam:   
A:   V25.43  Implanon Surveillance; NEXPALNON information & consent visit 
P:    Reviewed the following with patient: 
1. Other available contraceptives 
2. NEXPLANON benefits 
3. NEXPLANON insertion procedure / NEXPLANON removal procedure 
4. NEXPLANON ROD check procedure 
5. NEXPLANON problems, risks, side-effects 
6. NEXPLANON cost 
7. NEXPLANON Consent Form Reviewed and signed 
8. Patient to make insertion visit / follow up visit as desired 
 
Adopted the form (last revised 03/14) from University Health Services, Tang Center, University of 
California, Berkeley. 
  















Appendix D  Project Gantt Chart  
      Table 1.   Project Gantt Chart 
   Task start date duration complete date 
 Task1 Chart review 1/25/2014 49 3/15/2014 
 Task2 Data analysis 3/16/2014 35 4/20/2014 
 Task3 Staff training 3/20/2014 163 8/30/2014 
 Task4 Online Ad 10/1/2014 80 12/20/2014 
 Task4 Final prep 7/1/2014 91 9/30/2014 
 Task5 Service launch 10/1/2014 84 12/24/2014 
 Task6 f/u chart review 1/5/2015 31 2/5/2015 
 Task7 Data analysis 2/6/2015 22 2/28/2015 
 Task6 final report for audit 3/1/2015 29 3/30/2015 
 




Chart 1.  Project Gantt Chart









final report for audit
start date
duration




Appendix E   Failure Mode, Effect, and Criticality Analysis for LARC service 


























5 5 10  
Frequency of 
Failure Mode  
2 5 2  
Likelihood of 
Reaching Patient 
2 5 2  
Criticality of 
Failure Mode 
20 125 40  
Root Causes No standard 
clinical 
guidelines to 
require a back-up 
gynecologist   
No supervision for 
inexperienced 
providers 
Not familiar with 
possible adverse 























update skills;  
Risk prevention 
& elimination 






patient care and 
care transfer; 
 




Appendix F  Contraceptive Method Data Collection Form (2013 & 2014) 
 
  
< 20 21 - 24 25-29 > 30  < 6 m > 6 m  > 12m total
Appendix E-1.  Contraceptive Method Data Collection Form  (06/24-12/20/2013)





































**other includes not use any method, coitus interuptus, film, etc.
* "Condom" may include other types of barrier methods.
new form up to age 20 age 21 - 24 age 25 - 29 age 30 & > use < 6m use > 6 m use > 12m C/Initiate Total


















Appendix E-2.  Contraceptive Method Data Collection Form  (06/24-12/20/2014)




*other includes no BCM, coitus interuptus, film, etc.
* "Condom" may include other types of barrier methods.
XXXXXXXXXXXXXXXXXXXXXXXX




Appendix G-1  Initial WBS    
 
 































Staff Survey Patient Survey 





















Material Environment Measurement 






























Appendix J    
Table 1. Observation of Contraceptive Use from Women’s Health Visits in June-December 2013 
 
 
visits 2013 q4w Total < 24 yo OC/Patch/Ring Injection Implant IUC Other
6/24/2013 85 66(78%) 31/1/1 6 0 M4/P0 38
7/22/2013 62 48(77%) 33/2/1 1 0 M1/P2 23
8/19/2013 67 48(72%) 30/3/1 1 0 M4/P1 29
9/16/2013 223 116(52%) 109/6/10 20 2 M2/P2 75
10/14/2013 300 240(80%) 135/4/8 27 4 M6/P1 97
11/11/2013 294 222(76%) 126/11/11 21 4 M4/P5 112
Total visits 1031 733(71%) 464/28/32(50%) 76% (75) 10(1%) M21/P11(3%) 347(37%)
IUC-Intrauterine Contarceptives;  M-Mirena;  P-Paragard  
   
Chart 1  Current Contraceptive Used (June-December 2013) 
      














Appendix K-1   




          Month1 Month2 Month3 Month4 Month5 Month6 total 
LARC/units 
need per 





each month $2,571  $4,285  $2,571  $6,856  $6,856  $3,428  $27,424  
pre-paid 
(total of 15 
units) ($2,130) ($4,260) ($2,130) ($2,130)     ($10,650) 
          
A smaller number of LARC services will be expected for the first 6 months and during the quarter breaks. 
  
      Appendix K-2 
 Budget Projection for Implant Contraceptive (approved in late October, 2014) 
 
  Month1 Month2 Month3 Month4 Month5 Month6 total 
LARC/units 
need per 





each month $2,690  $5,380  $2,690  $7,170  $7,170  $3,580  $28,690  
pre-paid 
(total of 5 
units) ($1,980) ($1,320) 
  
    ($3,300) 
    





Appendix L    
Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use (Updated in June 2012) 
 
Medical Eligibility Criteria Categories 
1 = A condition for which there is no restriction for the use of the contraceptive method. 
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks. 
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method. 
4 = A condition that represents an unacceptable health risk if the contraceptive method is used. 
http://www.arhp.org/uploadDocs/choosingqrg.pdf  
   
 
 


















































































  I C I C I C I C I C I C 
Age  Menarche 
to <40=1 
Menarche to <18=1 Menarche to <18=2 Menarche to <18=1 Menarche to <20=2 Menarche to <20=2 
  >40=2 18-45=1 18-45=1 18-45=1 >20=1 >20=1 
   >45=1 >45=2 >45=1   
Anatomic 
abnormalities  
a) Distorted uterine cavity     4 4 
b) Other abnormalities     2 2 
Anemias a) Thalassemia 1 1 1 1 1 2 
 b) Sickle cell disease‡ 2 1 1 1 1 2 
 c) Iron-deficiency anemia 1 1 1 1 1 2 
Benign ovarian 
tumors 
(including cysts) 1 1 1 1 1 1 
Breast disease a) Undiagnosed mass 2* 2* 2* 2* 2 1 
 b) Benign breast disease 1 1 1 1 1 1 
 c) Family history of cancer 1 1 1 1 1 1 
 d) Breast cancer‡       
      i) current 4 4 4 4 4 1 
 ii) past and no evidence of 
current disease for 5 years 




a) < 1 month postpartum 3* 2* 2* 2*   
b) 1 month or more postpartum 2* 1* 1* 1*   
Cervical cancer Awaiting treatment 2 1 2 2 4 2 4 2 




 2 1 2 2 2 1 
Cirrhosis a) Mild (compensated) 1 1 1 1 1 1 




/Pulmonary    
embolism (PE) 
a) History of DVT/PE, not on 
anticoagulant therapy 
      
i) higher risk for recurrent 
DVT/PE  
4 2 2 2 2 1 
ii) lower risk for recurrent 
DVT/PE  
3 2 2 2 2 1 
b) Acute DVT/PE 4 2 2 2 2 2 
c) DVT/PE and established on 
anticoagulant therapy for at least 3 
months 
      
i) higher risk for recurrent 
DVT/PE  
4* 2 2 2 2 2 
ii) lower risk for recurrent 
DVT/PE  
3* 2 2 2 2 2 
d) Family history (first-degree 
relatives) 
2 1 1 1 1 1 
e) Major surgery       
(i) with prolonged 
immobilization 
4 2 2 2 2 1 
(ii) without prolonged 
immobilization 
2 1 1 1 1 1 
f) Minor surgery without 
immobilization 
1 1 1 1 1 1 
Depressive 
disorders 
 1* 1* 1* 1* 1* 1* 
Diabetes mellitus 
(DM)  
a) History of gestational DM only 1 1 1 1 1 1 
b) Non-vascular disease       
Diabetes mellitus 
(cont.) 
(i) non-insulin dependent 2 2 2 2 2 1 
(ii) insulin dependent‡ 2 2 2 2 2 1 
c) Nephropathy/ retinopathy/ 
neuropathy‡ 
3/4* 2 3 2 2 1 
d) Other vascular disease or 
diabetes of >20 years' duration‡ 
3/4* 2 3 2 2 1 
Endometrial 
cancer‡ 
 1 1 1 1 4 2 4 2 
Endometrial 
hyperplasia 
 1 1 1 1 1 1 
Endometriosis   1 1 1 1 1 2 
Epilepsy‡ (see also Drug Interactions) 1* 1* 1* 1* 1 1 
Gallbladder  
disease 
a) Symptomatic       
(i) treated by      
cholecystectomy 
2 2 2 2 2 1 
     (ii) medically treated 3 2 2 2 2 1 
(iii) current 3 2 2 2 2 1 
b) Asymptomatic 2 2 2 2 2 1 
Gestational 
trophoblastic  
a) Decreasing or 
undetectable ß-hCG levels 
1 1 1 1 3 3 

















































































  I C I C I C I C I C I C 
disease b) Persistently elevated 
ß-hCG levels or 
malignant disease‡ 
1 1 1 1 4 4 
Headaches a) Non-migrainous 1* 2* 1* 1* 1* 1* 1* 1* 1* 1* 1* 
b) Migraine            
i) without aura, age <35 2* 3* 1* 2* 2* 2* 2* 2* 2* 2* 1* 
ii) without aura, age >35 3* 4* 1* 2* 2* 2* 2* 2* 2* 2* 1* 




a) Restrictive procedures 1 1 1 1 1 1 
b) Malabsorptive procedures COCs: 3 3 1 1 1 1 
P/R: 1 
History of  a) Pregnancy-related 2 1 1 1 1 1 
cholestasis b) Past COC-related  3 2 2 2 2 1 
History of high  
blood pressure  
during pregnancy  
 2 1 1 1 1 1 
       
       
History of pelvic 
surgery 
 1 1 1 1 1 1 
HIV  High risk 1 1 1* 1 2 2 2 2 
HIV infected  
(see also Drug Interactions)‡ 
1* 1* 1* 1* 2 2 2 2 
AIDS  
(see also Drug Interactions) ‡ 
1* 1* 1* 1* 3 2* 3 2* 
Clinically well on therapy If on treatment, see Drug Interactions 2 2 2 2 




a) Adequately controlled 
hypertension 
3* 1* 2* 1* 1 1 
b) Elevated blood pressure levels 
(properly taken measurements) 
      
(i) systolic 140-159 or diastolic 
90-99 
3 1 2 1 1 1 
(ii) systolic ≥160 or diastolic 
≥100‡ 
4 2 3 2 2 1 
c) Vascular disease 4 2 3 2 2 1 
Inflammatory 
bowel disease 
(Ulcerative colitis, Crohn’s 
disease) 
2/3* 2 2 1 1 1 
Ischemic heart 
disease‡ 
Current and history of 4 2 3 3 2 3 2 3 1 
Liver tumors a) Benign       
 i) Focal nodular hyperplasia 2 2 2 2 2 1 
 ii) Hepatocellular adenoma‡ 4 3 3 3 3 1 
 b) Malignant‡ 4 3 3 3 3 1 
Malaria  1 1 1 1 1 1 
Multiple risk 
factors for arterial 
cardiovascular 
disease 
(such as older age, smoking, 
diabetes and hypertension) 
3/4* 2* 3* 2* 2 1 
Obesity 
 
a) >30 kg/m2 body mass index 
(BMI) 
2 1 1 1 1 1 
 b) Menarche to < 18 years and > 
30 kg/m2  BMI 
2 1 2 
 
1 1 1 
Ovarian cancer‡  1 1 1 1 1 1 
Parity a) Nulliparous 1 1 1 1 2 2 
 b) Parous 1 1 1 1 1 1 
Past ectopic 
pregnancy 




a) Past, (assuming no current risk 
factors of STIs) 
      
(i) with subsequent pregnancy 1 1 1 1 1 1 1 1 
 (ii) without subsequent 
pregnancy 
1 1 1 1 2 2 2 2 
 b) Current 1 1 1 1 4 2* 4 2* 
Peripartum 
cardiomyopathy‡  
a) Normal or mildly impaired 
cardiac function 
      
 (i) < 6 months 4 1 1 1 2 2 
 (ii) > 6 months 3 1 1 1 2 2 
 b) Moderately or severely 
impaired cardiac function 
4 2 2 2 2 2 
Postabortion a) First trimester 1* 1* 1* 1* 1* 1* 
 b) Second trimester 1* 1* 1* 1* 2 2 
 c) Immediately post-septic 
abortion 




a)  < 21 days 4 1 1 1   
b)  21 days to 42 days        
(i) with other risk factors for 
VTE 3* 1 1 1 
  

















































































  I C I C I C I C I C I C 
(ii) without other risk factors 
for VTE 
2 1 1 1   
c)  > 42 days 1 1 1 1   
Postpartum (in 





a) < 10 minutes after delivery of 
the placenta 
    2 1 
b) 10 minutes after delivery of the 
placenta to < 4 weeks 
    2 2 
c) > 4 weeks     1 1 
d) Puerperal sepsis     4 4 
Pregnancy   NA* NA* NA* NA* 4* 4* 
Rheumatoid  
arthritis 
a) On immunosuppressive therapy 2 1 2/3* 1 2 1 2 1 
 b) Not on immunosuppressive 
therapy 
2 1 2 1 1 1 
Schistosomiasis a) Uncomplicated 1 1 1 1 1 1 
 b) Fibrosis of the liver‡ 1 1 1 1 1 1 
Severe 
dysmenorrhea 









a) Current purulent cervicitis or 
chlamydial infection or gonorrhea 
1 1 1 1 4 2* 4 2* 
b) Other STIs (excluding HIV and 
hepatitis) 
1 1 1 1 2 2 2 2 
c) Vaginitis (including 
trichomonas vaginalis and 
bacterial vaginosis) 
1 1 1 1 2 2 2 2 
d) Increased risk of STIs 1 1 1 1 2/3* 2 2/3* 2 
Smoking a) Age < 35 2 1 1 1 1 1 
 b) Age > 35, < 15 cigarettes/day 3 1 1 1 1 1 
 c) Age > 35, >15 cigarettes/day 4 1 1 1 1 1 
Solid organ  
transplantation‡ 
a) Complicated 4 2 2 2 3 2 3 2 
b) Uncomplicated 2* 2 2 2 2 2 
Stroke‡ History of cerebrovascular 
accident 




a) Varicose veins 1 1 1 1 1 1 
b) Superficial thrombophlebitis 2 1 1 1 1 1 
       
Systemic lupus 
erythematosus‡ 
a) Positive (or unknown) 
antiphospholipid antibodies 
4 3 3 3 3 3 1 1 
 b) Severe thrombocytopenia 2 2 3 2 2 2* 3* 2* 
 c) Immunosuppressive treatment 2 2 2 2 2 2 2 1 
 d) None of the above 2 2 2 2 2 2 1 1 
Thrombogenic 
mutations‡ 
 4* 2* 2* 2* 2* 1* 
Thyroid disorders Simple goiter/ 
hyperthyroid/hypothyroid 
1 1 1 1 1 1 
Tuberculosis‡  
(see also Drug 
Interactions) 
a) Non-pelvic 1* 1* 1* 1* 1 1 
b) Pelvic 1* 1* 1* 1* 4 3 4 3 
Unexplained 
vaginal bleeding  
(suspicious for serious condition) 
before evaluation 
2* 2* 3* 3* 4* 2* 4* 2* 
Uterine fibroids  1 1 1 1 2 2 
Valvular heart  
disease 
a) Uncomplicated 2 1 1 1 1 1 




a) Irregular pattern without heavy 
bleeding 
1 2 2 2 1 1 1 
b) Heavy or prolonged bleeding 1* 2* 2* 2* 1* 2* 2* 
Viral hepatitis a) Acute or flare 3/4* 2 1 1 1 1 1 




a) Nucleoside reverse 
transcriptase inhibitors 




2* 2/3* 2* 
 b) Non-nucleoside reverse 
transcriptase inhibitors 
2* 2* 1 
 
2* 2/3* 2* 2/3* 2* 
 c) Ritonavir-boosted protease 
inhibitors  
3* 3* 1 
 
2* 2/3* 2* 2/3* 2* 
Anticonvulsant 
therapy 




3* 3* 1 
 
2* 1 1 
 b) Lamotrigine 3* 1 1 1 1 1 
Antimicrobial  
therapy 
a)  Broad spectrum antibiotics 1 1 1 1 1 1 
b) Antifungals 1 1 1 1 1 1 
c) Antiparasitics 1 1 1 1 1 1 
d) Rifampicin or rifabutin therapy 3* 3* 1 
 
2* 1 1 




I = initiation of contraceptive method; C = continuation of contraceptive method; NA = Not applicable 
* Please see the complete guidance for a clarification to this classification: www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm 
‡ Condition that exposes a woman to increased risk as a result of unintended pregnancy. 
 
  




Table 1. Description of Studies Included  
Study Year 
Published 












preferences by age 
LARCs were chose by 70% of 
study participants.  
Subcutaneous Implants were 
preferred among age 14-17 and 















No pregnancy per 100 women 
years were found in the IUD 
user group and 16.2 pregnancies 
per 100 women years in the non-










rates of LARCs 
At 6-month f/u, the continuation 
rate was 75% in the LNG-IUS 
group vs 45% in the Copper T 
IUD group.  100% of LNG-IUS 
group and 83% in Copper T 
group planned to continue the 











of LNG-IUS and 
ENG-implant use 
among age 20-35 
years European 
women 
The 12-month continuation rates 
were 93% in LNG-IUS group 
and 86% for the ENG-implant 
group. About 62% of LNG-IUS 
users were satisfied with their 




2009 A systematic 
review of 6 
cohort study 
and 7 case-
series studies   




The IUD has similar or better 
continuation rates compared to 
combined oral contraceptives.  
The cumulative pregnancy rate 
among IUD users was 2 % at 6 
months to 11% at 48 months.   
  




Table 2.  Evaluation of Studies Using the STROBE Checklist 
STROBE Mestad Fanarjian Godfrey Short Deans* 
1a Y Y Y Y Y 
1b Y Y Y Y Y 
2 Y Y Y Y Y 
3 Y Y Y Y Y 
4 Y Y Y Y Y 
5 Y Y Y Y Y 
6 Y Y Y Y Y 
7 Y Y Y Y Y 
8 Y Y Y Y N 
9 Y Y Y Y Y 
10 Y Y Y Y Y 
11 Y Y Y Y N 
12 Y Y Y Y N 
13 Y Y Y Y Y 
14 Y Y Y Y Y 
15 Y Y Y Y N 
16 Y Y Y Y N 
17 Y Y Y Y Y 
18 Y Y Y Y Y 
19 Y Y Y Y Y 
20 Y Y Y Y Y 
21 Y Y Y Y Y 
22 Y Y Y Y N 
Continued on next page   









Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of 
case ascertainment and control selection. Give the rationale for the choice of 
cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods 
of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number 
of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 




Case-control study—If applicable, explain how matching of cases and controls 
was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account 
of sampling strategy 
(e) Describe any sensitivity analyses 
Continued on next page  





Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background 
and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article 
(freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine 
at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org.  
  




Table 4.   Provider LARC Training Plan  
 Implant Contraceptive IUD 
Lecture All completed & certified 
 




individual practice model 
3 providers completed/a 
refresher lab needed  
Observation (optional) In progress 
 
Not approved/ prn 
Supervised insertion 3 cases  
 
5 cases 
Supervised removal 3 cases 
 
0 
  
 
